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Insulin resistance is a major metabolic 
disturbance in type 2 diabetes and is ob-
served primarily in the muscle, liver and 
adipose tissue. This thesis introduces a 
novel surrogate index to estimate hepatic 
insulin resistance. It further examines the 
tissue specificity of reported type 2 diabe-
tes risk loci in the liver and adipose tissue 
insulin resistance. The study compares 
the association of liver and muscle insulin 
resistance indices with cardiovascular 
risk factors. Insulin resistance in the liver 
correlates more strongly with various 
cardiovascular risk factors revealing a 
critical role of the liver in cardiovascu-
lar health. Finally, the thesis examines 
mainly insulin release and proinsulin 
processing as possible mechanisms for 
the association of several genetic risk loci 
with hyperglycemia.
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ABSTRACT
The prevalence of type 2 diabetes is increasing alarmingly worldwide and is
attributable to an increase in the prevalence of obesity and a sedentary lifestyle. The
two major pathophysiological features of type 2 diabetes are impaired insulin
secretion and insulin resistance. Impaired insulin secretion is mainly due to
pancreatic beta-cell dysfunction or/and decreased beta-cell mass. Insulin resistance is
observed predominantly in skeletal muscle, liver and adipose tissue. Insulin
resistance in these tissues is the underlying cause of several metabolic disturbances,
and plays a critical role not only in the pathogenesis of type 2 diabetes, but also in
the development of cardiovascular disease (CVD). Genome-wide association studies
have identified several gene loci associated with type 2 diabetes and hyperglycemia.
Most of these loci are known to be associated with insulin secretion and only a few
with insulin resistance. The main objective of this study was to investigate the role of
insulin resistance in insulin sensitive tissues, especially in the liver, in non-diabetic
participants.
A novel surrogate index for hepatic insulin resistance, Liver IR index,
was  developed.  Unlike  other  markers  that  include  only  insulin  and  glucose
measurements, Liver IR index takes into consideration several metabolic traits
related to hepatic insulin resistance, e.g. BMI, fat mass and high-density lipoprotein
cholesterol levels. This index strongly correlates with the direct measure of hepatic
insulin resistance based on the clamp technique with tracers. It was found that type 2
diabetes risk loci, rs1111875 of HHEX and rs5219 of KCNJ11, were significantly
associated with increased hepatic insulin sensitivity. The combined effect of five type
2 diabetes risk loci on liver insulin resistance was <2%. Therefore, the effect of
increased insulin sensitivity of HHEX and KCNJ11 loci on liver insulin sensitivity
seems to be minor and might be compensatory for their effects on the impairment of
insulin secretion. The Pro12Pro genotype of PPARG was associated with decreased
adipose tissue insulin sensitivity. It was also noted that insulin resistance,
particularly  in  the  liver,  plays  a  major  role  in  the  adverse  changes  in  the  CVD risk
factors, mainly those related to dyslipidemia (total triglycerides, apolipoprotein B
VI
and total cholesterol levels) and low-grade inflammation. Finally, several single
nucleotide polymorphisms associated with fasting hyperglycemia, indicating that
these loci mainly regulate insulin release (basal: G6PC2, MTNR1B, and DGKB;
glucose-stimulated: MTNR1B, TCF7L2, CRY2, FADS1, GCK and SLC30A8) and/or
proinsulin processing (MADD, TCF7L2, SLC30A8 and GCKR). Only one locus
(GCKR) was associated with insulin sensitivity.
National Library of Medical Classification: WG 120, WI 702, WK 810, WK 820, WK 880
Medical Subject Headings: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Risk Factors; Insulin
Resistance; Liver; Adipose Tissue; Hyperglycemia; Blood Glucose; Genes; Genetic Loci;
Dyslipidemias; Inflammation; Polymorphism, Single Nucleotide
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11. Introduction
Diabetes mellitus is a chronic disease currently affecting an estimated 346 million
people worldwide, as reported by the World Health Organisation (2011). This
number is expected to grow up to 439 million adults by 2030 [1]. The prevalence of
type 2 diabetes has risen alarmingly in the recent past owing to the trends towards
increasing obesity and adoption of a sedentary lifestyle, and type 2 diabetes is now
being diagnosed also in children and adolescents. As a consequence, the prevalence
of microvascular and macrovascular complications is increasing, leading to severe
outcomes such as blindness, kidney failure and cardiovascular disease (CVD).
Several non-modifiable risk factors such as age, gender, family history,
race and ethnicity increase the risk of type 2 diabetes, along with various modifiable
risk  factors  such  as  obesity,  physical  inactivity,  diet,  smoking,  elevated  blood
pressure and dyslipidemia. Identical twin pairs show a higher concordance rate for
diabetes than do dizygotic twins [2,3]. The first-degree relatives of diabetic
individuals have up to four times greater lifetime risk of developing diabetes
compared to the general population [4]. The lifetime risk of developing type 2
diabetes is 40% for individuals with one parent with type 2 diabetes, and 70% if both
parents are affected [4]. The likelihood of developing type 2 diabetes is greater in
certain ethnic groups. For example, the risk of diabetes in African-Americans,
Hispanics, and Native Americans is approximately 2, 2.5, and 5 times greater,
respectively, than in Caucasians [5].
Disturbances in normal glucose homeostasis cause impaired glucose
tolerance that further progresses to overt diabetes. One of the major
pathophysiological features leading to type 2 diabetes is impaired insulin secretion.
Impaired insulin secretion is observed when the pancreatic beta-cells are not able to
produce enough insulin to normalize glucose levels. The beta-cells initially respond
to  elevated  glucose  levels  by  producing  higher  amounts  of  insulin,  resulting  in
hyperinsulinemia.  Over  time,  the  beta-cells  lose  this  capability  and  thus,  insulin
levels decline. Impaired insulin secretion is observed early in the natural history of
diabetes and has a strong genetic basis [6,7]. This impairment in insulin secretion is
attributable to defective beta-cell function or/and decreased beta-cell mass.
Insulin resistance, the other major pathophysiological feature of type 2
diabetes,  is  observed  prominently  in  skeletal  muscle,  liver  and  adipose  tissue.  The
reduced sensitivity of these tissues to insulin is observed in individuals with type 2
2diabetes. Insulin resistance in these tissues is the underlying cause of several
metabolic disturbances, playing a critical role not only in the pathogenesis of type 2
diabetes, but also in other complex diseases, e.g. CVD. It associates with several
abnormalities in the lipid and lipoprotein levels and blood pressure, resulting in an
increased risk of CVD [8]. Thus, insulin resistance is considered as an independent
risk factor for atherosclerosis and CVD [8,9]. CVD is the leading cause of mortality in
individuals with type 2 diabetes.
Hyperglycemia is the primary consequence of insulin resistance in
combination with impaired insulin secretion. Hyperglycemia, an elevation in fasting
or postprandial glucose levels, is a prediabetic state that greatly increases the risk for
future diabetes and CVD [10]. It is also considered as a major initiator of many
diabetic microvascular complications such as retinopathy, neuropathy and
nephropathy [11]. Hyperglycemia induces cellular dysfunction and damage through
a variety of mechanisms such as oxidative stress leading to alterations in the
expression and function of several genes and proteins [11].
Genetic association studies can identify gene variants that predispose to
complex diseases such as type 2 diabetes and CVD. Over the past few years, several
genome-wide association studies have resulted in the identification of novel risk loci
or polymorphisms associated with type 2 diabetes and also with other metabolic
traits, including hyperglycemia [12-20]. The majority of these risk loci are associated
with impaired insulin secretion, and only a few with insulin resistance.
The current study aimed to examine tissue-specific insulin resistance,
mainly in the liver, and the effect of type 2 diabetes loci on tissue-specific insulin
resistance and its implication in CVD in a large cohort of non-diabetic individuals.
Furthermore, the study investigated the association of loci regulating fasting
hyperglycemia with indices of insulin secretion and insulin sensitivity.
2. Review of the literature
2.1 PATHOPHYSIOLOGY OF TYPE 2 DIABETES
The major metabolic disturbances leading to type 2 diabetes are insulin resistance
and impaired insulin secretion. There is a dynamic balance between insulin
sensitivity  and insulin  secretion [6].  Type 2  diabetes  develops  when this  balance  is
3disrupted, i.e. when the increase in insulin secretion is unable to compensate for the
prevailing insulin resistance.
2.1.1 Insulin secretion
The secretion of insulin from the pancreatic beta-cells is a complex process. The most
important  stimulus  for  insulin  secretion,  glucose,  enters  the  cytoplasm of  the  beta-
cell via a facilitated glucose transporter, SLC2A2. The presence of glucose inside the
cell is recognized by a glucokinase that acts as a glucose sensor. Glucose is
metabolized to ATP through a series of biochemical pathways. Elevation of the
ATP/ADP ratio triggers the closure of the ATP-sensitive K+ channels, leading to cell
membrane depolarization which in turn results in the opening of voltage-dependent
Ca2+ channels causing extracellular calcium to enter into the cell that acts as a trigger
of insulin exocytosis [21].
Insulin release from the pancreatic beta-cells occurs in a biphasic pattern
upon  induction  by  glucose.  The  first  phase  is  an  acute  transient  phase.  This  is  an
initial burst of insulin that occurs within a few minutes after the elevation in glucose
levels. The second phase of insulin release that follows is slower and more sustained.
Studies based on isolated beta-cells have revealed that the first phase burst of insulin
release arises from the readily releasable pool of insulin granules present at the
plasma membrane, whereas the second phase insulin secretion occurs from newly
synthesized insulin granules [21-24].
Impaired insulin secretion is the major pathophysiological mechanism
leading to type 2 diabetes. In hyperglycemic conditions, the beta-cells secrete
increasing amounts of insulin in attempts to overcome insulin resistance but with
time, insulin secretion declines. In type 2 diabetes, the first phase of insulin release is
often blunted or absent and the second phase is also diminished [7,25,26]. The defect
in insulin secretion mainly occurs due to decreased beta-cell mass or impaired beta-
cell signaling or genetic abnormalities [27-29]. A reduction of about 20-40% in the
beta-cell mass can be measured in type 2 diabetes subjects. The beta-cell mass might
be reduced due to impaired neogenesis or enhanced apoptosis. Approximately 60-
70% of beta-cell function is already lost in individuals with impaired glucose
tolerance [30]. A genetic basis of beta-cell dysfunction has been demonstrated in
studies based on first degree relatives of type 2 diabetic subjects and in twin studies
[31,32].  The  two  incretins,  GLP-1  and  GIP,  play  a  major  role  in  stimulating  insulin
secretion following oral glucose administration. This potentiating effect of the
4incretins is reported to be defective in type 2 diabetic subjects and their first-degree
relatives [33].
Insulin is a heterodimeric protein comprising of a 21 amino acid A-chain
and a 30 amino acid B-chain linked by disulfide bridges. Preproinsulin, the early
precursor of insulin, is larger and comprises of 110 amino acids. It includes a 24
amino  acid  signal  sequence  and  a  35  amino  acid  connecting  peptide  linking  the  A
and B chain as shown in Figure 1.
Figure 1. Precursors of insulin (adapted from [34])
Insulin is produced in the endoplasmic reticulum in its precursor form
and packaged into secretory vesicles in the Golgi apparatus. The secretory granules
are the major site of insulin processing. The main enzymatic machinery involves
proprotein convertase 1/2 and carboxypeptidase E that convert preproinsulin into a
mature heterodimeric insulin molecule and C-peptide. Only a small part (<10%) of
the newly synthesized proinsulin escapes from this conversion process. Therefore,
the relative proportion of proinsulin to insulin (PI/I ratio) provides an estimate for
the efficiency of proinsulin processing [35].
Basal intact proinsulin levels have been shown to be higher not only in
obese and non-obese subjects with type 2 diabetes but also in obese subjects without
type 2 diabetes [36]. A high PI/I ratio is associated with elevated glucose levels,
impaired insulin secretion, insulin resistance and increased risk of type 2 diabetes
[37-40].
2.1.2 Insulin resistance
Ever since its initial identification by Himsworth (1936), who classified subjects as
being either insulin sensitive or insulin insensitive [41], insulin resistance has been
5recognized as a characteristic feature of a spectrum of metabolic disturbances
including obesity, hypertension and type 2 diabetes. Insulin resistance is defined as a
decreased responsiveness of target tissues to normal circulating levels of insulin.
Studies  based  on  euglycemic  insulin  clamp  have  provided  direct  quantitative
evidence that the progression from normal to impaired glucose tolerance is
associated with the development of severe insulin resistance.
Figure 2. Insulin signaling pathway (modified from [42])
Insulin exerts its biological functions by binding to the insulin receptor,
which initiates a cascade of signaling events [43], as depicted in Figure 2. The
binding of insulin to the extracellular -subunit of the insulin receptor stimulates
autophosphorylation on multiple tyrosine residues in the cytoplasmic portion of the
transmembrane -subunit. This results in the activation of its intrinsic tyrosine
kinase, which in turn catalyses the phosphorylation of intracellular substrates
including the insulin receptor substrate (IRS). Once phosphorylated, IRS proteins
bind and activate several Src homology 2 (SH2) domain proteins including the p85
regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase). PI 3-kinase is
known to play a central role in insulin-stimulated intracellular translocation of
GLUT-4 and glucose uptake in adipose tissue and skeletal muscle. Activated PI 3-
kinase generates lipid phosphatidylinositol 3,4,5-trisphosphate (PIP3). The increase
6in the level of PIP3 leads to the activation of a protein kinase cascade, first
stimulating the protein pyruvate dehydrogenase kinase, PDK1, which
phosphorylates and activates serine/threonine kinase, Akt (also known as protein
kinase B) that further interacts with several other downstream effectors.
Several  defects  in  insulin  signaling  involving  the  IR/IRS/PI  3-
kinase/PKC/Akt/SLC2A4 cascade have been detected in subjects with insulin
resistance [43,44]. Thus, it is possible that decreased expression or increased
degradation of  these  key components  of  insulin  signaling might  be  responsible  for
the development of insulin resistance.
Inflammatory cytokines such as tumour necrosis factor- (TNF-) and
interleukin-6 (IL-6) have been linked to insulin resistance [45]. A key mechanism by
which cytokines such as TNF- induce insulin resistance involves site-specific serine
phosphorylation of IRS-1 [46]. Serine phosphorylation might induce the dissociation
of IRS proteins from the insulin receptor or hinder access to tyrosine
phosphorylation sites of IRS proteins or induce IRS protein degradation. The insulin
signaling pathway also regulates Forkhead transcription factors, mainly Foxo1 and
Foxa2. In insulin resistant conditions, the constitutive activation of Foxo1 and Foxa2
results in elevated gluconeogenesis, hyperglycemia and high levels of lipid oxidation
[47].
Insulin resistance and endothelial dysfunction commonly occur together
and both traits can be detected early in the pathogenesis of atherosclerosis [48].
Insulin  exerts  its  vascular  effects  primarily  by  augmenting  the  availability  of
endothelium-derived nitric oxide (NO), a potent vasodilator. In experimental
conditions mimicking the state of insulin resistance, endothelial-mediated
vasodilation  was  found  to  be  impaired,  partly  due  to  the  inability  of  insulin  to
stimulate the activity of the key enzyme responsible for NO synthesis, nitric oxide
synthase (NOS), in vascular endothelial cells [48-50].
Insulin resistance is traditionally defined only by disturbances in
glucose metabolism. This glucocentric view, that states that hyperglycemia is the
primary disease caused by a combination of insulin resistance and beta-cell loss, is
challenged by a more lipocentric view. Hyperglycemia, insulin resistance and beta-
cell loss could be secondary to lipotoxicity or ectopic lipid deposition at least to some
extent. Insulin resistance is the major identifiable defect in subjects at risk for type 2
diabetes and might precede its development by several years [51-53]. Insulin
7resistance is also important in the development of CVD. This process can include
several stages as depicted in Figure 3.
Figure 3. Different stages in the progression of insulin resistance to type 2 diabetes and
cardiovascular disease (adapted from [54])
Other genetic or acquired factors that could lead to insulin resistance
include  mainly  obesity  and  the  presence  of  excess  glucocorticoids  as  observed  in
Cushing’s syndrome or in patients receiving other steroid therapies, or subjects with
hormonal imbalances as in polycystic ovarian syndrome, and lipid accumulation in
the liver.
2.2 TISSUE-SPECIFIC INSULIN RESISTANCE
Whole-body glucose homeostasis can be maintained when all the tissues are
normally sensitive to insulin. Insulin resistance has tissue-specific effects that have
been demonstrated in studies based on transgenic mice, e.g. insulin receptor
knockout mice. Mice lacking the muscle insulin receptor alone are characterized by
reduced insulin-stimulated muscle glucose uptake, but total-body glucose
8homeostasis remains normal [55]. Adipose tissue insulin receptor knockout mice
exhibited impaired adipose tissue glucose uptake but were protected against obesity,
glucose intolerance, and dyslipidemia and manifested a prolonged lifespan. In
contrast, knockout of the insulin receptor in the liver resulted in both fasting and
postprandial hyperglycemia and the subsequent development of peripheral (muscle)
insulin resistance [55].
In humans, skeletal muscle accounts for ~80% of the insulin-stimulated
glucose uptake, liver ~15-20% and adipose tissue <5% [6]. However, in the insulin
resistant state, all these tissues together contribute to the development of
hyperglycemia as presented in Figure 4.
Figure 4. Major metabolic defects in tissues causing hyperglycemia (adapted from [56])
2.2.1 Skeletal muscle
Skeletal muscle tissue accounts for up to 80% of insulin-mediated glucose uptake in
the post-prandial state [6]. Thus, insulin resistance in skeletal muscle contributes
significantly to disturbances in glucose homeostasis, and is present even decades
before beta-cell failure and overt hyperglycemia [57,58]. In agreement with this
notion, even lean normal glucose-tolerant offspring of two parents with type 2
diabetes exhibit moderate to severe skeletal muscle insulin resistance [59-64].
9Skeletal muscle stores 1-2% of its tissue mass as glycogen. Glycogen
synthesis in the skeletal muscle is one of the primary pathways of glucose disposal.
In subjects with type 2 diabetes, baseline glycogen concentrations are ~30% lower
than in matched controls, indicating that the process of glycogen synthesis has been
profoundly impaired [65]. During hyperinsulinemia, type 2 diabetic patients display
a blunted elevation in intramyocellular glucose-6-phosphate concentrations in
comparison with their age-weight matched control subjects [66], suggesting that
glucose transport mediated by GLUT-4, and/or its phosphorylation, mediated by
hexokinase, are the rate limiting steps in insulin-stimulated glucose disposal in
skeletal muscle. Similar findings have been observed in lean, insulin-resistant
offspring of type 2 diabetic patients [67]. A reduction of GLUT-4 mediated glucose
transport, leading to lower insulin stimulated glycogen synthesis, is considered as
the central feature in skeletal muscle insulin resistance [68].
Mitochondria are the major organelles involved in fatty acid oxidation
and they are known to have a major role in energy metabolism. Normal glucose-
tolerant subjects with both parents affected with diabetes, have reduced expression
of key mitochondrial genes which regulate oxidative metabolism in skeletal muscle
[69]. In contrast, mitochondria from normal glucose-tolerant subjects without any
family history of diabetes respond to insulin by increasing ATP production by 90%,
whereas  mitochondria  from insulin  resistant  offspring increase  ATP production by
only 5% [70-72].
In young and lean insulin resistant subjects, skeletal muscle insulin
resistance leads to increased levels of plasma triglycerides and lower plasma levels
of high-density lipoprotein cholesterol [73]. The energy derived from ingested
carbohydrates is diverted away from muscle glycogen synthesis into increased
hepatic de novo lipogenesis that might be partly due to the upregulation of the
insulin-dependent sterol regulatory element binding protein-1c, SREBP1c, a master
transcriptional regulator of lipogenic enzymes, thus leading to the development of
atherogenic dyslipidemia [74,75].
2.2.2 Liver
The liver plays a major role in glucose homeostasis. It has a primary role in
endogenous glucose production or gluconeogenesis during fasting, and storage of
glucose as glycogen (glycogenesis) in the fed state, both processes being regulated by
insulin. Insulin resistance in the liver results in impaired suppression of hepatic
10
glucose production, a trait that can be observed not only in type 2 diabetes but also
in pre-diabetes [76-78].
The  major  contributors  to  endogenous  glucose  production  (EGP)  are
gluconeogenesis and glycogenolysis. The dynamic equilibrium between glucose
production and glucose utilization is regulated by insulin and glucagon. The liver is
an important tissue for glucose homeostasis, and it is the predominant site for EGP
with only a minor contribution made by the kidney (<20%). The liver is involved in
directing glucose fluxes both during transition from fasting to the fed state and
under  pathological  conditions  such  as  diabetes  mellitus.  Subjects  with  type  2
diabetes exhibit increased endogenous glucose production, and synthesize only 25-
45% of hepatic glycogen when compared with non-diabetic individuals [79]. Thus,
defective regulation of glycogenolysis as well as gluconeogenesis occurs as a
consequence of hepatic insulin resistance, as observed in obese non-diabetic and
type 2 diabetic humans.
Insulin primarily suppresses EGP via a direct interaction with hepatic
receptors  or  indirectly  through  its  action  on  lipolysis  in  the  fat  cell.  In  the  liver,  it
mediates  its  inhibitory  effects  on  glucose  production  by  inhibiting  the  two  key
gluconeogenic enzymes, phosphoenolpyruvate carboxykinase and glucose-6-
phosphatase. In individuals with abnormal glucose tolerance, and especially in
individuals with type 2 diabetes, the suppression of EGP is inadequate and
contributes to both fasting and postprandial hyperglycemia [77,78].
Hyperglycemia is an important determinant of vascular complications
of diabetes. Short-term fluctuations in glycemic control, acute hyperglycemia, and
also chronic hyperglycemia play a key role in the pathogenesis of vascular
complications associated with diabetes. Both are involved in the development of
various microvascular and macrovascular complications [80]. Hyperglycemia is not
only a consequence of, but also an important factor for the worsening of both insulin
resistance and insulin deficiency as it results in glucose toxicity that further
aggravates the pathophysiological state, mainly by increasing oxidative stress [81].
Studies that have employed isotope tracer techniques to assess visceral
fat metabolism in vivo in obese subjects have shown that ~20% of non-essential fatty
acids (NEFA) delivered into the liver are derived from lipolysis of visceral fat [82].
Thus, insulin resistance in the liver could be mainly due to visceral obesity and
chronic inflammation associated with it. Obesity is characterized by the production
of excess NEFA and inflammation is characterized by abnormal production of
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cytokines and adipokines e.g., TNF-, IL-6, leptin and resistin. Increased NEFA flux
from adipose tissue to the liver also leads to dyslipidemia, mainly via increased
production of very-low density lipoprotein (VLDL) particles [83].
2.2.3 Adipose tissue
Adipose tissue, mainly white adipose tissue, acts as a reservoir of energy that is
stored in the form of fat. More importantly, adipose tissue is an endocrine organ that
secretes several cytokines/adipokines and which modulates whole body glucose
metabolism. The importance of fat tissue in glucose homeostasis has been
demonstrated in fatless mouse models [84,85]. These mice are extremely insulin
resistant, and introduction of fat restores their sensitivity to insulin.
The major effect of insulin on adipose tissue is to activate lipoprotein
lipase that binds NEFAs and glycerol together to form triglycerides, the storage form
of  fat.  Adipose  tissue  is  extremely  sensitive  to  insulin  concentrations,  inhibiting
lipolysis at insulin concentrations that are much lower than those needed to inhibit
hepatic glucose production or to stimulate muscle glucose uptake. However, in
subjects with type 2 diabetes, lipolysis is resistant to insulin when compared to non-
diabetic subjects [86].
It is widely accepted that adipose tissue plays a central role in the
development of insulin resistance [87,88]. In insulin-resistant states, there is marked
adipocyte resistance to the antilipolytic effect of insulin, resulting in the elevation of
plasma NEFA levels. Fasting and postprandial NEFA levels have generally been
found to be elevated in obesity and type 2 diabetes [89,90]. During nutritional excess,
adipocytes become hypertrophic and develop a gene expression pattern that closely
resembles that of macrophages [91], leading to the secretion of various adipokines.
Thus, the overproduction of the proinflammatory cytokines such as IL-6, TNF- and
CRP  and  a  deficiency  of  the  anti-inflammatory  cytokines  like  adiponectin
exacerbates insulin resistance.
Recent studies have indicated that disturbances in the PPAR and
CCAAT/enhancer-binding protein (C/EBP) signaling play an important role in
adipose tissue as they are essential for adequate adipogenesis, metabolic regulation,
and adipose tissue insulin sensitivity [92].
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2.3 IDENTIFICATION OF RISK LOCI FOR TYPE 2 DIABETES
2.3.1 Family based linkage analysis and candidate gene approach
Linkage  analysis  is  most  useful  when  the  disease  under  investigation  follows  a
monogenic form of inheritance with a large effect size. This technique is based on the
use of genetic markers in a family pedigree coupled with phenotypic information to
identify chromosomal regions showing a linkage with a specific trait or disease.
Causative genetic variations of several monogenic forms of diabetes, e.g. maturity-
onset diabetes of the young and neonatal diabetes, have been successfully identified
using this approach [93].
Only two genes associated with type 2 diabetes have been reported to be
identified by linkage analyses, CAPN10 and TCF7L2, although the CAPN10 locus
could not be replicated in genome-wide association studies [94,95].
The candidate gene approach focuses on a specific candidate gene or a
selected genetic region chosen based on a known biological function. This approach
is biased in assuming that a specific locus causes a disease based on prior
knowledge. Many candidate genes have been investigated based on this principle.
However, only a few genes for type 2 diabetes, such as PPARG and KCNJ11, have
been identified with this approach [96-98].
2.3.2 Genome-wide association studies
With  the  advent  of  genome-wide  association  (GWA)  studies,  owing  to  the
completion of Human Genome Project and Hapmap Project [99], it became possible
to test hundreds of thousands of SNPs simultaneously for their association with
complex diseases. This method allowed the discovery of multiple gene variants each
individually having only a small effect. Almost all disease categories have been
addressed, including metabolic, neurodegenerative and cardiovascular diseases and
several types of cancer. The first six GWA studies for type 2 diabetes performed in
2007, reported more than 10 new genetic loci that significantly modified the risk of
type 2 diabetes [12-20]. In addition, PPARG, KCNJ11 and TCF7L2 were confirmed as
risk loci for type 2 diabetes in these studies.
After a series of GWA studies that reported several new loci associated
with type 2 diabetes, meta-analyses combining several GWA studies were
performed [16]. These studies combined several GWA scans that were based on
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large populations, and thus had substantial power to detect genetic variants with
small effect sizes. This approach identified several new genetic loci for type 2
diabetes.
Additional GWA studies that reported association with continuous
glycemic traits, such as fasting glucose, fasting insulin, HOMA-B and HOMA-IR led
to the identification of new genetic variants [18]. After completion of deep
sequencing of the human genome, it might be possible to identify additional risk loci
for type 2 diabetes. The various loci associated with type 2 diabetes or other
glycemic traits are listed in Table 1.
2.4 GENETIC LOCI ASSOCIATED WITH TYPE 2 DIABETES OR
HYPERGLYCEMIA
The variants can be broadly classified based on their effects either on beta-cell
function or insulin sensitivity or loci with unknown role in type 2 diabetes, and are
briefly described below.
2.4.1 Variants regulating -cell function
ADRA2A, encodes the adrenergic  alpha-2A  receptor,  which  is  a  member  of  the  G-
protein coupled receptor superfamily. This gene is located on chromosome 10q24-26
and interestingly, it contains no introns. ADRA2A inhibits lipolysis and thus
promotes weight gain [101]. Since Adra2a mediates adrenergic suppression of
insulin secretion, Adra2a knockout mice exhibit enhanced insulin secretion [102], and
animals with beta-cell specific overexpression of Adra2a are glucose-intolerant [103].
A recent study revealed that the risk allele carriers of variant rs553668, exhibited
overexpression of the receptor and as a consequence, they displayed reduced insulin
secretion and had an increased risk of type 2 diabetes [104].
C2CD4B, encoding C2 calcium-dependent domain containing 4B, is located on
chromosome 15q22.2. The biological function of this protein coding gene is yet
unknown, but it might play a role in inflammation as its expression is upregulated
by cytokines [105]. Recent studies have reported the association of a SNP rs11071657
with fasting hyperglycemia and a reduced glucose-stimulated insulin response
[18,106].
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Table 1. Genetic  variants  associated  with  type  2  diabetes,  insulin  secretion,  insulin
resistance and other glycemic traits (modified from Grarup et al. [100])
Gene Lead SNP Risk allelefrequency
Type
of
study
GWA trait Other reported association with physiologicphenotypes
Variants regulating -cell function
ADRA2A rs10885122 0.90 MA FG Reduced insulin release during OGTT
C2CD4B rs11071657 0.59 FG Reduced insulin release during OGTT
Increased fasting proinsulin
CDC123/ rs12779790 0.23 MA T2D Reduced insulin release during OGTT
CAMK1D MA Reduced arginine-stimulated and second-phase
glucose-stimulated insulin release during
hyperglycemic clamp
CDKAL1 rs10946398 0.31 GWA T2D Impaired conversion of proinsulin to insulin
Reduced insulin release during OGTT
Reduced insulin release after IV glucose
stimulation
Reduced birth weight
CDKN2A rs10811661 0.79 GWA T2D Reduced insulin release during OGTT
CDKN2B Reduced insulin release during IVGTT
CENTD2 rs1552224 0.88 MA T2D Lower HOMA-B
DGKB/ rs2191349 0.47 MA FG, T2D Reduced insulin release during OGTT
TMEM195
FADS1 rs174550 0.63 MA FG Reduced insulin release during OGTT
G6PC2 rs560887 0.70 MA FG Increased insulin release during OGTT
HOMA-B Increased insulin release during IVGTT
HbA1c Increased basal hepatic glucose production
Decreased risk of T2D
GCK rs1799884 0.20 MA FG, T2D,
HbA1c
Increased glucose levels during OGTT
Reduced insulin release derived from OGTT
GIPR rs10423928 0.18 MA 2 h-G Reduced insulin release during OGTT
Increased fasting proinsulin
Impaired incretin effect
GLIS3 rs7034200 0.53 MA FG Reduced insulin release during OGTT
HHEX rs1111875 0.56 GWA T2D Reduced insulin release during OGTT
IDE rs5015480 GWA Borderline significant reduced insulin release
during IV glucose
stimulation
Reduced birth weight
IGF2BP2 rs4402960 0.29 GWA T2D Reduced insulin release during OGTT
Reduced insulin release during IVGTT
Reduced insulin release after IV tolbutamide
stimulation
HNF1A rs7957197 0.85 MA T2D
HNF1B rs4430796 0.43 CS T2D
JAZF1 rs864745 0.52 MA T2D Reduced insulin release derived from OGTT
KCNJ11/ rs5219 0.50 CS T2D Reduced insulin release during OGTT
ABCC8 Increased glucagon levels during hyperglycemic
clamp
KCNQ1 rs2237895 0.61 GWA T2D Reduced insulin release during OGTT
Reduced glucose-stimulated incretin secretion
MADD rs7944584 0.69 MA FG Higher fasting proinsulin
MTNR1B rs10830963 0.30 FG, Reduced insulin release during OGTT
T2D, HbA1c Reduced insulin released during IVGTT
PROX1 rs340874 0.50 MA FG, T2D Reduced insulin release during OGTT
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SLC30A8 rs13266634 0.75 GWA T2D, FG Impaired conversion of proinsulin to insulin
Reduced insulin release during OGTT
Reduced insulin release during IVGTT
TCF7L2 rs7901695 LA T2D, FG, 2 h-
G
Impaired conversion of proinsulin to insulin
rs7903146 0.25 Reduced insulin release during OGTT
Reduced incretin effect
Reduced glucagon levels
THADA rs7578597 0.92 MA T2D Reduced GLP-1—and arginine-stimulated insulin
release during hyperglycemic clamp
TSPAN8 rs7961581 0.23 MA T2D Reduced insulin release during OGTT
WFS1 rs10010131 0.27 CS T2D Reduced insulin release during OGTT
Reduced GLP-1 induced insulin release during
hyperglycemic clamps
Variants regulating insulin sensitivity
ADAMTS9 rs4607103 0.81 MA T2D Reduced insulin-stimulated glucose uptake
during hyperinsulinemic-euglycemic clamp
Increased glucose-stimulated insulin release
DUSP9 rs5945326 0.12 MA T2D
GCKR rs780094 0.62 MA FG, T2D,
2 h-G,
triglyceride
Increased insulin resistance derived from fasting
and OGTT
IGF1 rs35767 0.90 MA FI Increased HOMA-IR
Decreased OGTT-based insulin sensitivity
IRS1 rs2943641 0.61 CS T2D Increased insulin resistance derived from fasting
and OGTT
rs1260326 0.40 Increased insulin-stimulated hepatic glucose
output
KLF14 rs972283 0.55 MA T2D Increased fasting insulin and HOMA-IR
PPARG rs1801282 0.92 CS T2D Decreased insulin sensitivity derived from IVGTT
and hyperinsulinemic-euglycemic clamp
Variants with unknown function
ADCY5 rs11708067 0.78 MA FG, 2 h-G,
T2D, HOMA-B
Decreased birth weight
BCL11A rs243021 0.46 MA T2D
CHCHD9 rs13292136 0.93 MA T2D
CRY2 rs11605924 0.54 MA FG
HMGA2 rs1531343 0.10 MA T2D
NOTCH2 rs10923931 0.11 MA T2D
PRC1 rs8042680 0.22 MA T2D
RBMS1 rs7593730 MA T2D Increased HOMA-IR
SLC2A2 rs11920090 0.85 MA FG
TP53INP1 rs896854 0.48 MA T2D
VPS13C rs17271305 0.42 MA 2 h-G
ZFAND6 rs11634397 0.56 MA T2D
ZBED3 rs4457053 0.26 MA T2D
MA=meta analysis, CS=candidate gene study, LA=linkage analysis, FG=fasting
glucose, 2h-G=2 hr glucose
CDC123/CAMK1D, encoding cell division cycle 123 homolog and
calcium/calmodulin-dependent protein kinase 1 D, is located on chromosome 10p13.
16
CAMK1D plays a role in granulocyte function and it may also affect beta-cell
function by reducing the beta-cell mass due to enhanced apoptosis [107]. The SNP
rs12779790, reported to be associated with type 2 diabetes, belongs to this genomic
region. This variant was also associated with a beta-cell defect [108].
CDKAL1, encoding cyclin-dependent kinase 5 regulatory sub-unit associated protein
1-like 1, is located on chromosome 6p22.3. This gene is expressed in pancreatic islets,
skeletal  muscle  and  brain.  A  study  based  on Cdkal1 knockout mice reported that
Cdkal1 controls the first-phase insulin exocytosis by facilitating ATP generation, and
altering  KATP channel  and  Ca2+ channel activity [109]. It has been recently reported
that it is a t-RNA modification enzyme required for the accurate translation of
codons [110]. Several SNPs belonging to this gene region, mainly rs7754840, have
been associated with type 2 diabetes and decreased first phase insulin secretion
[13,111,112].
CDKN2A/CDKN2B, encoding Cyclin-dependent kinase inhibitor 2A/B, are located
adjacent to each other on chromosome 9p and encode two different isoforms of
cyclin-dependent kinase (CDK) inhibitors. CDKs are protein kinases that have a role
in  regulating  the  cell  cycle.  CDK  inhibitors  are  mainly  considered  to  be  tumor-
suppressor genes. Their function is largely unknown in type 2 diabetes, but variants
of these genes, rs10811661 and rs564398, have been reported to be associated with
type 2 diabetes [14,15,17]. Both proteins encoded by CDKN2B and CDKN2A are
expressed in pancreatic islets and seem to be involved in the regulation of pancreatic
beta-cell replication [113,114].
CENTD2 or ARAP1, encoding ArfGAP with RhoGAP domain, ankyrin repeat and
PH domain 1, is located on chromosome 11q13.4. It has been identified as a
component of the machinery that controls the endocytic trafficking and signalling of
the EGF receptor [115]. Variant rs1552224 has been identified as a risk locus for type
2 diabetes [20]. Its association with increased plasma glucose values and decreased
glucose-stimulated insulin release has been recently reported [116].
DGKB, encoding diacylglycerol kinase beta, is located on chromosome 7p21.2. This
enzyme regulates the intracellular concentration of the second messenger
diacylglycerol  and  thus  plays  a  key  role  in  many  cellular  processes.  It  is  a  lipid-
regulating enzyme and it catalyzes the phosphorylation of diacylglycerol to
phosphatidic acid [117]. Dgkb knockout mice display various behavioral
abnormalities and exhibit impaired GSK3B signaling [118]. Another study showed
that DGK inhibition results in increased protein kinase C-alpha activity, reduced
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glucose-induced insulin receptor activation, and GLUT4 translocation [119]. The
rs2191349 risk allele near DGKB/TMEM195, was identified as a fasting glucose
enhancing allele and it also decreased glucose-stimulated insulin secretion [18,106].
FADS1, encoding fatty acid desaturase 1, is a member of the fatty acid desaturase
(FADS) gene family located on chromosome 11q12.2-q13.1. The enzyme plays a
crucial role in desaturation and elongation of polyunsaturated fatty acids. Fatty acid
desaturases are therefore considered as important factors in the pathogenesis of
lipid-induced insulin resistance. It has been reported that insulin can induce the
expression of FADS1 and FADS2 in a time- and dose-dependent manner [120].
FADS1 SNP rs174550 has been shown to associate with fasting glucose levels [18].
G6PC2, encoding the enzyme glucose-6-phosphatase, catalytic, 2, is located on
chromosome 2q24.3. This enzyme catalyses the terminal step in gluconeogenic and
glycogenolytic pathways, promoting the release of glucose into the bloodstream.
G6pc2 knockout mice are reported to have reduced fasting plasma glucose levels
[121]. The SNP rs560887 was reported to be associated with fasting glucose, insulin
secretion and type 2 diabetes [18,122].
GCK, encoding Glucokinase, is located on chromosome 7p15.3-p15.1 and is
expressed in the liver and pancreas. This enzyme catalyses the first rate limiting step
in the metabolism of glucose and is termed as a glucose sensor in the pancreas. Beta-
cell specific Gck knockout mice do not survive due to diabetes. In contrast, liver-
specific Gck knockout mice survive and exhibit mild hyperglycemia and defective
glycogen synthesis [123]. GCK mutations in humans have been reported to cause
maturity-onset diabetes of the young, type 2 (MODY2) [124]. The risk allele of SNP
rs1799884 has been associated with fasting glucose, impaired insulin secretion and
type 2 diabetes [18,122].
GIPR, encoding the gastric inhibitory polypeptide (GIP) receptor, is located on
chromosome 19q13.3. GIPR is a transmembrane protein G-protein coupled receptor
found in pancreatic beta-cells and also other tissues. The incretin hormone, GIP,
mediates early insulin secretion from the beta-cells after a meal. Gipr knockout mice
have higher blood glucose levels with an impaired initial insulin response after oral
glucose load [125]. SNP rs10423928 of GIPR was  reported to  be  associated with 2h
glucose [19]. Additionally, lower insulin secretion along with a diminished incretin
effect has been observed in carriers of the risk-allele.
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GLIS3,  encoding  GLIS  family  zinc  finger  3,  is  a  member  of  the  GLI-similar  zinc
finger protein family located on chromosome 9p24.2. GLIS3 encodes a nuclear
protein  with  five  C2H2-type  zinc  finger  domains.  This  protein  functions  as  both  a
repressor and activator of transcription and is specifically involved in the
development of pancreatic beta-cells. It regulates insulin gene expression and
interacts with various transcription factors like Pdx1, MafA that are involved in
pancreatic development [126]. Glis3 mutant mice develop neonatal diabetes,
evidenced by hyperglycemia and hypoinsulinemia [127]. GLIS3 SNP rs7034200 has
been implicated in fasting glucose homeostasis [18].
HHEX, hematopoietically expressed homeobox, located on chromosome 10q23.33,
encodes a transcription factor that is expressed in the embryonic ventral-lateral
foregut that gives rise to the ventral pancreas and the liver. Hhex knockout  mice
display early embryonic lethality, due to impaired forebrain, liver and thyroid
development [128]. The mechanism by which the HHEX variant  alters  the  risk  of
type 2 diabetes, awaits further investigation. The variant might have a role in altered
organogenesis as demonstrated by the developmental defects in HHEX knockout
mice [129]. SNP, rs7923837, located in the 3’-flanking region of the gene has been
reported to associate with glucose-stimulated insulin secretion and type 2 diabetes
[130,131].
IGF2BP2,  encodes  insulin-like  growth  factor  2  (IGF-2)  mRNA  binding  protein  2
which  is  a  member  of  the  IGF-2  mRNA-binding  protein  (IMP)  family.  The  gene  is
located on chromosome 3q27.2 and the protein has been implicated in RNA
localization, stability and translation that are essential for normal embryonic growth
and  development.  It  is  expressed  in  the  brain  and  several  tissues  including  the
pancreas [132]. The predisposition to type 2 diabetes, conferred by the SNP
rs4402960, is mainly attributable to its association with first-phase insulin secretion
and impaired beta-cell function [111].
HNF1A, encoding hepatocyte nuclear factor homeobox A, is located on chromosome
12q24.2. HNF1A is a transcription factor which is required for the expression of
several liver-specific genes. Mutations in this gene cause maturity onset diabetes of
the young type 3 (MODY3) [133]. SNP rs7957197 was reported to be associated with
type 2 diabetes [20].
HNF1B, encoding hepatocyte nuclear factor 1-beta, is a member of the
homeodomain-containing superfamily of transcription factors located near
chromosome 17q21.3. HNF1B binds to DNA as a homodimer or a heterodimer with
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a  related  protein,  HNF1-alpha.  This  transcription  factor  is  known  to  play  a  role  in
regulating the development of pancreas. Selective deletion of Hnf1b in beta-cells in
mice leads to impaired glucose tolerance, dysregulated islet gene expression, and
reduced glucose-stimulated insulin secretion [134]. A mutation in the HNF1B causes
MODY5 [135]. SNP rs4430796 has been shown to have modest effects on the risk of
type 2 diabetes [136].
JAZF1, Juxtaposed with another zinc finger gene 1, encodes a nuclear protein that
functions as transcriptional repressor. JAZF1 is located on chromosome 7p15. In
adipocytes  and  liver  cells,  JAZF1 reduces lipid synthesis and increases lipolysis,
mainly by down-regulating the levels of sterol regulatory element-binding protein 1,
acetyl-coenzyme A carboxylase, and mRNA expression of fatty acid synthetase and
by increasing hormone-sensitive lipase mRNA expression [137]. Jazf1
overexpression studies in mice heart, showed cardiac defects and upregulated levels
of pro-apoptotic genes [138]. JAZF1 SNP rs864745 has been associated with lower
insulin secretion and elevated type 2 diabetes risk [16].
KCNJ11, encoding potassium inwardly-rectifying channel, subfamily J, member 11,
is located on chromosome 11p15.1. KCNJ11 encodes the pore-forming subunit Kir6.2
of the ATP-sensitive potassium channel of beta-cells, which couples glucose sensing
with membrane depolarization and exocytosis of insulin granules. KCNJ11
mutations prevent electrical activity and insulin release from INS-1 cells by
increasing the KATP current and hyperpolarizing the beta-cell membrane [139]. The
best studied and confirmed type 2 diabetes risk variant E23K (rs5219) has been
shown in vitro to increase the probability of the channel’s open state, to enhance its
activity, and to impair its ATP sensitivity, thereby inhibiting beta-cell excitability
and insulin release [140,141]. Similar associations with impaired insulin release and
type 2 diabetes have been demonstrated in various population-based studies
[98,142]. A previous study also reported that carriers of the rs5219 risk allele had
increased hepatic insulin sensitivity [143].
KCNQ1, encodes potassium voltage-gated channel, KQT-like subfamily, member 1,
that is required for repolarization phase of the action potential. KCNQ1 is located on
chromosome 11p15.5. It is likely that KCNQ1 influences K+-dependent insulin
signaling on glucose metabolism. Its overexpression in pancreatic beta-cells has led
to the lowering of action potential and caused impaired insulin release [144]. Various
polymorphisms of KCNQ1, mainly rs2237897, have been shown to associate with
reduced glucose-stimulated insulin secretion and type 2 diabetes [145]. The risk
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allele is further reported to be associated with higher fasting glucose and lower beta-
cell function [146,147].
MADD, encodes a mitogen-activated protein-kinase (MAPK) activating death
domain protein and is located on chromosome 11p11.2. This enzyme interacts with
TNF-alpha receptor 1 to activate MAPK and propagates the apoptotic signal [148]. It
is also a GDP/GTP Exchange Protein which cycles Rab3A between active/inactive
forms. Thus, MADD is considered to have a role in apoptosis and exocytosis [149]. A
SNP of this gene, rs7944584, was initially associated with fasting hyperglycemia [18].
Recently, it was also shown to be associated with impaired proinsulin to insulin
conversion [150].
MTNR1B, encoding melatonin receptor 1B, is located on chromosome 11q21-q22. Its
endogenous ligand, melatonin, is a neurohormone that mediates circadian
rhythmicity and appears to influence insulin secretion and glucose levels [151,152].
Expression of melatonin receptors has been demonstrated in mouse, rat, and human
pancreatic islets (MT1 in -cells and MT2 in -cells) [153]. Both MT1 and MT2 are G-
protein coupled receptors and are proposed to exert inhibitory effects on insulin
secretion. The risk allele of MTNR1B SNP rs10830963 has been identified as a fasting
glucose enhancing allele and is associated with impaired early insulin secretion and
type 2 diabetes [18,154].
PROX1, encoding Prospero homeobox 1, is a transcription factor and considered an
early specific marker for liver and pancreatic development [155]. PROX1 is located
on chromosome 1q41. It has also been considered as a tumor-suppressor gene and its
expression is altered in liver tumors [156]. This gene is regulated by -catenin-
TCF/LEF activation downstream of Wnt signaling [157]. The risk allele of PROX1
SNP rs340874 has been shown to be associated with elevated fasting glucose levels
and type 2 diabetes risk [18].
SLC30A8, encoding the zinc-transporter ZnT8, is located on chromosome 8q24.11. It
is highly expressed in the pancreatic beta-cells and it colocalises with insulin in the
beta-cell [158]. It acts as a zinc transporter in beta-cells and is important for storage
and maturation of insulin within cytoplasmic secretory granules. Slc30a8 knockout
mice have a reduced Zinc content in islets and also lower plasma insulin
concentrations [159]. The variant in SLC30A8, rs13266634, that has been reported to
be associated with type 2 diabetes, may affect the function of the transporter by
altering zinc accumulation in insulin granules and hence influence insulin stability
and insulin trafficking [160].
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TCF7L2, encoding transcription factor 7-like 2, is located on chromosome 10q25.3.
TCF7L2 is a component of the bipartite transcription factor complex that is involved
in the Wnt signaling pathway [161]. In human and murine islets, TCF7L2 is required
for beta-cell survival and beta-cell proliferation, as well as for glucose and incretin-
stimulated insulin secretion [162,163]. Interestingly, Tcf7l2 null mice display
enhanced glucose tolerance, suggesting that over-expression of this gene is
associated with increased risk of type 2 diabetes [164]. TCF7L2 SNP rs7903146 is
currently the strongest risk locus reported to be associated with type 2 diabetes with
an odds ratio of 1.4 and its susceptibility has been confirmed in many ethnic groups
[165,166]. This variant has been associated with glucose-stimulated and incretin-
stimulated insulin secretion and also with impaired proinsulin to insulin conversion
[167-169].
THADA, encoding thyroid adenoma associated protein, is located on chromosome
2p21. This region is characterized by the presence of frequent structural
chromosomal rearrangements in benign adenomas of the thyroid. Hence, THADA
has  been  reported  to  play  a  role  mainly  in  thyroid  adenomas.  Additionally,  it  has
been implicated in the death receptor pathway suggestive of a role in apoptosis
[170]. A SNP in THADA, rs7578597 has been reported to be associated with type 2
diabetes [16].
TSPAN8, encoding tetraspanin 8, is located on chromosome 12q14.1-q21.1. TSPAN8
is a protein belonging to the transmembrane 4 superfamily. This family of proteins
mediates signal transduction events that play a role in the regulation of cell
development, activation, growth and motility. TSPAN8 has  been  shown  to  play  a
prominent role in metastasis and is implicated in hepatocellular carcinoma [171].
Tspan8 deficient mice exhibited reduced body weight although no changes in fasting
insulin or glucose levels were detected [172]. The SNP rs7961581 located in this gene
was reported to be associated with type 2 diabetes [16].
WFS1, encoding Wolfram syndrome 1, is located on chromosome 4p16.1. It encodes
an endoplasmic reticulum transmembrane protein. Mutations in the gene are
associated with Wolfram syndrome that mainly affects the central nervous system.
Mice with disrupted WFS1 gene developed glucose intolerance, even overt diabetes,
due to  insufficient  insulin  secretion [173].  Recently,  it  was  demonstrated that  Wfs1
localises to the secretory granules in the pancreatic beta-cells and Wfs1 null mice
display impaired proinsulin processing [174]. SNPs in WFS1 have been shown to be
associated with decreased insulin secretion and the risk of type 2 diabetes [175,176].
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2.4.2 Variants regulating insulin sensitivity
ADAMTS9, encoding ADAM metallopeptidase with thrombospondin type 1 motif,
9, is a member of the ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family. The gene encoding ADAMTS9 is located on
chromosome 3p14.1. ADAMTS9 is a secreted metalloprotease that cleaves two
proteoglycans, versican and aggrecan. It is expressed in several tissues, including
skeletal muscle and pancreas. The first evidence for an association of a variant of this
gene with type 2 diabetes emerged from a meta-analysis and a consequent study
indicated that it might affect insulin sensitivity [16, 177].
DUSP9, encoding dual specificity phosphatase 9, is located on chromosome Xq28.
DUSP9 is a phosphatase that negatively regulates members of the MAP kinase
superfamily. DUSP9 has been reported to negatively regulate insulin signaling and
contribute to the pathogenesis of insulin resistance [178]. A variant of DUSP9,
rs5945326, has been reported to increase the risk of type 2 diabetes primarily through
its effect on insulin action [20].
GCKR, encodes a glucokinase regulatory protein, and is located on chromosome
2p23. GCKR inhibits glucokinase in liver and pancreatic islet cells. Gckr knockout
mice show a parallel loss of GCK protein levels and activity in the liver, resulting in
altered glucose metabolism and impaired glycemic control [179]. GCKR rs780094 has
been associated with susceptibility to type 2 diabetes, increased fasting plasma
glucose levels, low triglycerides levels and increased HOMA-IR [180].
IGF1, encoding Insulin like growth factor 1, is located on chromosome 12q23.2.
Several metabolic disorders have been demonstrated in Igf-1 deficient transgenic
mice that include lipid abnormalities, insulin resistance, and decreased bone density
[181]. Liver-specific Igf-1 deficient mice, develop insulin resistance in the liver,
muscle and adipose tissues [182]. The fasting insulin–raising allele at IGF1 rs35767
was associated with lower insulin sensitivity [183].
IRS1, Insulin receptor substrate 1, is located on chromosome 2q36 that encodes a
protein which is phosphorylated by insulin receptor tyrosine kinase. Irs1 deficient
mice have been reported to display a phenotype of growth retardation and insulin
resistance [184,185]. Mutations in this gene are associated with type 2 diabetes and
susceptibility to insulin resistance. A genetic variant near IRS1, rs2943641, has been
associated with insulin resistance, hyperinsulinemia and type 2 diabetes [186].
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KLF14, Kruppel-like factor 14, encodes a member of the Kruppel-like zinc finger
family of transcription factors located on chromosome 7q32.3. This family plays a
key role in regulating cellular differentiation and tissue development [187]. KLF14
has been recently identified as a regulator of adipose gene expression [188]. In
addition to type 2 diabetes, a variant in this gene region, rs972283 is associated with
high-density lipoprotein (HDL) cholesterol levels [20,189].
PPARG2, encoding peroxisome proliferator-activated receptor  (PPAR), is located
on chromosome 3p25. PPAR is a lipid-activated nuclear receptor and transcription
factor.  It  plays  a  fundamental  role  in  adipogenesis  and  insulin  sensitivity  by
regulating transcriptional activity of various genes. PPAR belongs to the nuclear
hormone receptor superfamily and is a central regulator of adipogenesis and
lipogenesis [190,191]. Selective disruption of PPAR2 in mice causes a phenotype of
an overall reduction in white adipose tissue, less lipid accumulation, and decreased
expression of adipogenic genes in adipose tissue and impaired insulin sensitivity
[192]. The most intensely studied and confirmed type 2 diabetes risk SNP rs1801282
(Pro12Ala polymorphism) of PPARG2 has been associated with insulin resistance
[96].
2.4.3 Variants with unknown function
ADCY5, encoding a protein that belongs to the adenylate cyclase family of enzymes,
is located on chromosome 3q13.2-q21. Adenylyl cyclases mediate G protein-coupled
receptor signaling through the synthesis of the second messenger, cAMP. ADCY5
belongs to the calcium-inhibited family of adenylate cyclase isoforms. The risk allele
of SNP rs11708067 has been associated with fasting hyperglycemia, impaired
proinsulin conversion and type 2 diabetes [18,19,150].
BCL11A, B-cell CLL/lymphoma 11A, encoding a zinc-finger protein, is located on
chromosome 2p16.1. BCL11A is a potent silencer of fetal hemoglobin and plays a
role in coordinating the switch from fetal to adult hemoglobin [193]. BCL11A has
been reported to act as a transcriptional repressor that interacts with several
proteins, including BCL6, COUP-TF, and SIRT1 [194]. Variants belonging to this
genic region have been associated with type 2 diabetes [16].
CHCHD9, coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 9, is
located on chromosome 9q21.31. Its function is largely unknown. A SNP of
CHCHD9, rs13292136, has been associated with type 2 diabetes [20].
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CRY2, encoding cryptochrome 2 (photolyase-like), is located on chromosome
11p11.2. The cryptochrome class of proteins has a role in circadian control of gene
expression that also include cAMP signaling and hepatic gluconeogenesis [195]. Cry1
and Cry2 double knockout mice present with increased CREB activity, expression of
gluconeogenic genes, and higher fasting blood glucose levels [196]. SNP rs11605924
has been associated with elevated fasting glucose and type 2 diabetes [18,197].
HMGA2, high  mobility  group  AT-hook  2,  is  located  on  chromosome  12q15.  The
encoding  protein  contains  structural  DNA-binding  domains  and  may  act  as  a
transcriptional regulating factor. It has also been implicated in adipocyte
differentiation in a study where knockout mice demonstrated resistance to diet-
induced obesity [198]. A SNP belonging to this genic region, rs1531343, is associated
with type 2 diabetes [20].
NOTCH2, belongs to the Notch family that plays a role in a variety of developmental
processes. The gene is located on chromosome 1p13-p11. This protein functions as a
receptor for membrane bound ligands, and may play a role in vascular, renal and
hepatic development. Notch-2 was recently identified as a novel target for -catenin-
dependent Wnt signaling that is involved in pancreatic development and insulin
secretion [199]. NOTCH2 SNP rs10923931 has been associated with type 2 diabetes
[16].
PRC1, encoding protein regulator of cytokinesis 1, is located on chromosome
15q26.1. It is a substrate of several cyclin-dependent kinases. It has a role in
microtubule formation that play a critical role in processes such as cell migration and
division [200]. A SNP rs8042680 has been associated with type 2 diabetes [20].
RBMS1, encoding RNA binding motif, single stranded interacting protein 1, is
located on chromosome 2q24.2. It belongs to a family of proteins that binds to single
stranded RNA/DNA and has been implicated in diverse functions as DNA
replication, gene transcription, cell cycle progression and apoptosis. A variant in this
region, rs7593730, has been associated with type 2 diabetes, fasting glucose and
HOMA-IR [201].
SLC2A2, encodes solute carrier family 2, member 2, and is located on chromosome
3q26.1-q26.2. It is a facilitated glucose transporter observed mainly in the liver and
pancreatic beta-cells. Its expression is suggested to be regulated by HNF-1alpha and
HNF-3beta [202]. As expected, Slc2a2 knockout mice develop hyperglycemia and
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impaired glucose tolerance [203]. SNP rs11920090 has been associated with fasting
glucose levels [18].
TP53INP1, encoding tumor protein p53 inducible nuclear protein 1, is located on
chromosome 8q22. Tp53inp1 has been implicated in several types of carcinoma.
Overexpression of TP53INP1 induces G1 arrest and increases p53-mediated
apoptosis indicating its role in regulating cell cycle progression and apoptosis [204].
Interestingly, the p53-p53INP1 pathway has been identified as a molecular
mechanism through which the other important type 2 diabetes gene, TCF7L2, affects
beta-cell survival [205]. A variant near this genic region, rs896854, has been
associated with type 2 diabetes [20].
VPS13C, encoding vacuolar protein sorting 13 homolog C, is located on chromosome
15q22.2. The VPS family of proteins are large proteins with a ubiquitous expression
[206]. A variant in this region, rs17271305, has been associated with 2-h glucose
levels [19].
ZFAND6,  encoding  zinc  finger,  AN1-type  domain  6,  is  located  on  chromosome
15q25.1. This gene plays a role in the TNFalpha signaling pathway [207]. A SNP,
rs11634397, belonging to this region has been associated with type 2 diabetes [20].
ZBED3,  encodes  a  zinc  finger,  BED  domain-containing  3  protein  and  is  located  on
chromosome 5q13.3. It has been identified as an Axin-binding protein that is
involved in modulating Wnt/beta-catenin signaling [208]. A variant from this
genomic region has been reported to be associated with type 2 diabetes [20].
2.5 CARDIOVASCULAR DISEASE
CVD is a major worldwide public health problem and the number one cause of
death in the industrialized countries. Cardiovascular death rates are either already
high or appear to be climbing in countries where diabetes is prevalent. It has been
estimated that by 2030, the mortality due to CVD will increase to almost 23.6 million
people (mainly from CAD) as compared to an estimated 17.1 million in 2004 (WHO).
CVD is projected to remain the single leading cause of death. Moreover, CVD
remains the most important cause of morbidity and mortality in patients with type 2
diabetes.
The  risk  of  developing  CVD  is  significantly  increased  in  subjects  with
type 2 diabetes. Adults with diabetes are two to four times more likely to have heart
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disease or stroke than adults without diabetes. The risk of cardiac mortality in
diabetic subjects is comparable to the risk of non-diabetic subjects after a myocardial
infarction [209].
2.5.1 CVD risk factors
CVD risk factors can be classified as traditional or non-traditional risk factors (Fig 5).
A majority of these risk factors are modifiable.  The traditional risk factors for CVD
include elevated blood pressure, smoking, high low density lipoprotein (LDL)
cholesterol, low HDL cholesterol and diabetes. The non-traditional risk factors
include insulin resistance, endothelial dysfunction, inflammation, microalbuminuria,
impaired  fibrinolysis  etc.  [210].  Several  of  these  risk  factors  such  as  hypertension,
hyperinsulinemia, dyslipidemia, obesity, thrombosis formation are already present
in  the  pre-diabetic  state  [211].  However,  these  risk  factors  frequently  cluster  and
interact with each other. Insulin resistance, causing various metabolic disturbances,
leads to CVD and hence it is also sometimes referred to as the cardiometabolic
syndrome. The most important risk factors including mainly the traditional risk
factors that explain 75-90% of all CVD events are briefly described below.
Figure 5. Traditional and non-traditional risk factors for CVD [210]
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2.5.1.1 Age, gender and family history of CVD
Age, gender and family history are the major non-modifiable risk factors for CVD.
Various pathophysiological features such as the increase in the size of cardiac
myocytes with a corresponding decrease in their number, thickening of arterial
walls, vascular stiffness, hypertension are observed in elderly subjects [212].
In  men,  the  onset  of  CVD  occurs  earlier  than  in  women  probably  as  a
consequence of the differences in the sex hormones that affect HDL cholesterol levels
[213]. Several other CVD risk factors e.g., diabetes mellitus, previous myocardial
infarction, alcohol consumption etc., are more prevalent in men until the age of 45-50
years, later they become comparable with those in age-matched women [214]. The
cumulative risk of CAD in men by the age of 70 is 30% and by age of 90 years is 48%.
Women typically develop CAD about 10 years later than men with a cumulative risk
of 15 and 30% by the ages of 70 and 90 years, respectively [215].
CVD has a strong genetic component as demonstrated in several family
and twin studies. Furthermore, animal models and genetic association studies
support its strong genetic basis. Although advancing age enhances the risk,
approximately 8% of the cases are diagnosed before age 50 [215]. A significant
difference in concordance of CAD deaths was observed in monozygotic twins as
compared with dizygotic twins in both men and women; 39 vs 26% and 44 vs 14%,
respectively. Recent genome-wide association studies have identified a large number
of variants associated not only with CVD risk but also with various intermediate
phenotypes such as LDL, HDL, TG and total cholesterol and CRP levels [216-218].
2.5.1.2 Elevated blood pressure
Elevated blood pressure is a well-known risk factor for CVD. Smoking, obesity and a
high intake of salt lead to the elevation of blood pressure. Elevated blood pressure
clusters with dyslipidemia, glucose intolerance and obesity and thus significantly
enhancing the risk of CVD [219]. Insulin resistance is often associated with these
pathophysiological traits [220].
Systolic blood pressure is considered to be a stronger predictor of CVD
risk than diastolic blood pressure [221]. High blood pressure has adverse affects on
the arteries imposing a mechanical stress on the arterial walls resulting in their
enlargement and thickening. Elevated blood pressure has been associated with long-
term mortality from CVD [222].  Men and women with high-normal blood pressure
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at baseline examination have been shown to have a high incidence of CVD than
those with optimal blood pressure [223].
2.5.1.3 Smoking
Smoking is a significant and independent risk factor for the development and
progression of CVD. It acts synergistically with other conventional risk factors,
greatly increasing the baseline risk associated with each risk factor individually and
significantly reducing the age of onset [224].
Smoking is associated with increased levels of inflammatory markers
and accelerated atherosclerosis [225]. Smokers often have high levels of total
cholesterol, LDL cholesterol and total triglycerides and lower levels of HDL
cholesterol than non-smokers [226]. Smokers were reported to have relative risk of
myocardial infarction of 2.24 times higher in females and 1.43 times higher in males,
when compared with non-smokers [227]. Smoking cessation has been clearly shown
to significantly improve the health status and to reduce several CVD risk factors
[227]. Besides the well-documented risk for CVD, there is also evidence for an
increased risk of the development of type 2 diabetes. Heavy smokers have a higher
relative risk of diabetes (OR 1.94) compared with non-smokers [228-230].
2.5.1.4 Dyslipidemia
Dyslipidemia  plays  a  major  role  in  the  pathogenesis  of  CVD.  As  a  consequence  of
increased lipolysis, the high flux of NEFA to the liver results in
hypertriglyceridemia. Elevated triglyceride level increases the risk of CVD [231].
VLDL, the major carrier of triglycerides, are hydrolyzed by lipoprotein lipase
generating smaller and denser VLDL that are subsequently converted to IDL [232].
IDL  particles  undergo  further  catabolism  to  form  LDL.  Triglyceride  enrichment  of
LDL results  in  the  formation of  small,  dense  LDL particles.  These  small  and dense
LDL  particles  are  more  common  in  subjects  with  CVD  and  these  particles  are
considered to be highly atherogenic due to their delayed clearance [233,234].
HDL plays a major role in reverse cholesterol transport from endothelial
cells  to  the  liver  which  is  an  important  anti-atherogenic  role  played  by  HDL.
Additionally, HDL has anti-apoptotic activity [235] and anti-inflammatory actions
[236] that are atheroprotective. In the insulin resistant state, increased transfer of
triglycerides from VLDL to HDL results in the formation of HDL particles that are
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smaller and denser and are cleared more rapidly, contributing to the decreased HDL
levels. Therefore, low HDL cholesterol levels increase the risk of coronary heart
disease [237].
The presence of small, dense LDL particles, increased levels of plasma
triglycerides and decreased levels of HDL cholesterol represent the atherogenic
lipoprotein phenotype. This phenotype is also observed in insulin resistant states
such as in obesity and type 2 diabetes.
2.5.1.5 Type 2 diabetes
Type 2 diabetes has long been recognized as an independent risk factor for
CVD. Various metabolic abnormalities that are initiated long before the diagnosis of
type 2 diabetes contribute to two-fold increase in the CVD risk in impaired glucose
tolerant states and to a four-fold increase in CVD risk in diabetic states [238].
Hyperglycemia, impaired insulin action and concomitant hyperinsulinemia increase
the risk for CVD in subjects with pre-diabetes and diabetes [9,211,239-242].
The presence of high levels of both fasting and 2h glucose is associated
with an enhanced risk of CVD. Moreover, a graded relationship between fasting and
2h glucose with cardiovascular events was apparent even for glucose levels that
were below the diabetic threshold [242]. High glucose could be causally related to
CVD through a number of mechanisms particularly, increased oxidative stress.
Furthermore, elevations in the glucose levels are confounded by other CVD risk
factors like hyperinsulinemia, hyper-triglyceridemia, obesity and hypertension [240-
242] resulting in various microvascular and macrovascular complications.
Insulin resistance per se is associated with a 1.5-2 fold increase in the
incidence of CVD. A clear relationship has been noted between insulin resistance
and carotid intima-media thickness, a surrogate marker for CVD [243]. Insulin
resistance is well correlated with central obesity, lipid abnormalities and
hypertension and clustering of these metabolic abnormalities, results in
atherosclerosis and other heart-related disorders.
2.5.1.6 Other cardiovascular risk factors
Physical inactivity and obesity. Physical inactivity is associated with an increased
risk of CVD. A study based on meta-analysis reported a relative risk of death from
coronary heart disease of 1.9 when subjects with sedentary occupations were
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compared with those in active occupations [244]. Physical activity improves several
CVD risk factors such as blood pressure, lipid levels and insulin sensitivity. Obesity
is  associated  with  an  increased  risk  of  morbidity  and  mortality  as  well  as  reduced
life expectancy. A genetic predisposition, increased caloric intake or decreased
energy expenditure or a combination of these traits are responsible for the current
epidemic  of  obesity.  It  is  an  independent  risk  factor  for  CVD,  and  enhanced  CVD
risk has also been observed in obese children [245,246]. Weight loss leads to
significant improvements in CVD risk factors [247-249].
C-reactive protein. Inflammation plays a key role in atherosclerosis and CVD [250].
High levels of hs-CRP have been shown to be an independent predictor of CVD risk
in non-diabetic subjects and in type 2 diabetes subjects [251]. Beyond its role as a
CVD risk marker, it might have a direct role in atherogenesis [252,253], as it co-
localizes with the membrane attack complex in early atheromatous lesions that leads
to cell lysis and death. The levels of CRP, along with other complement proteins, are
substantially upregulated in the atheromatous plaque [253].
Adiponectin. Adiponectin is one of the most abundant adipokines. It has insulin
sensitising effects in several tissues. Adiponectin also has anti-inflammatory and
anti-atherogenic properties. Secretion of adiponectin is reduced as adipose tissue
mass increases [254]. Serum adiponectin is negatively correlated with adverse
features of the metabolic syndrome as well as other associated features of insulin
resistance and conventional cardiovascular risk factors. Serum adiponectin levels are
lower in subjects with obesity [255], in subjects with CAD, as well as in those with
type 2 diabetes, compared to controls. They are especially low in patients with both
type 2 diabetes and CAD [256].
31
3. Aims of the study
The  major  aim  of  the  study  was  to  investigate  the  mechanisms  and  genetic
regulation of insulin resistance in insulin sensitive tissues, especially in the liver.
The specific aims of the study were as follows:
1) To develop a novel marker of hepatic insulin resistance,
2) To examine the effects of SNPs increasing the risk of type 2 diabetes on liver
and adipose tissue insulin sensitivity,
3) To evaluate the association between liver insulin resistance and the levels of
CVD risk factors,
4) To investigate the association of the SNPs regulating the levels of fasting
glucose with indices of insulin release, proinsulin conversion and insulin
sensitivity.
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4. Subjects and methods
4.1 SUBJECTS
The EGIR-RISC study (Study I)
A sample of 368 clinically healthy non-diabetic men (n=183) and women (n=185)
from the RISC study (age 43.0±8.2 years, BMI 26.0±4.0 kg/m2; mean±SD) was used to
develop and validate the surrogate index of liver IR. In this sample, 288 participants
had normal glucose tolerance and 80 had either impaired fasting glucose or
impaired glucose tolerance or both [257]. All participants were recruited from 19
research centres in 14 European countries. The protocol was approved by the local
Ethics Committees and all participants gave written informed consent. The inclusion
criteria  of  the  study  participants  and  the  study  protocol  have  been  described
previously [258].
The METSIM study (Studies II-IV)
Metabolic Syndrome in Men (METSIM) study is a population-based cross-sectional
study. It includes participants (age 57.2±7.1 years, BMI 26.8±3.8 kg/m2) who were
randomly selected from the population register of Kuopio town, Eastern Finland
(population of 95,000).
Study II included 8,460 non-diabetic participants. This study involved
two parts: 1) genetic association analyses that included 6,733 non-diabetic men (age
57.0±6.9 years, BMI 26.8±3.8 kg/m2; mean±SD) who were genotyped for the SNPs
being investigated; 2) gene expression study that included 41 obese participants (age
44.2±8.3 years, BMI 45.5±6.1 kg/m2, mean±SD; 11 men, total 18 subjects with type 2
diabetes) from an ongoing study, including participants who were undergoing
bariatric  surgery  at  the  Kuopio  University  Hospital  and  who  also  underwent  liver
biopsy.
Studies III and IV involved 8,750 non-diabetic men. Out of 8,750 non-
diabetic subjects, 3,034 (34.7%) men had normal glucose tolerance (NGT), 4,345
(49.7%) had isolated impaired fasting glucose (IFG), 312 (3.6%) had isolated
impaired glucose tolerance (IGT) and 1,059 (12.1%) had IFG and IGT, according to
the ADA criteria [253]. All studies were approved by the Ethics Committee of the
University of Eastern Finland and Kuopio University Hospital, and were carried out
in accordance with the Helsinki Declaration. All study participants gave written
informed consent.
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Table 2. Baseline  characteristics  of  non-diabetic  participants  of  the  METSIM  and  RISC
studies
Variable METSIM RISC
N 8750 368(183)*
Age, years 57.2±7.1 43±8.2
Body mass index, kg/m2 26.8±3.8 25.9±3.9
Fasting plasma glucose, mmol/l 5.7±0.5 5.0±0.6
2h plasma glucose, mmol/l 6.0±1.7 5.7±1.4
Fasting plasma insulin, pmol/l 57.3±40.9 38.0±21.5
*(N) – male subjects
4.2 METHODS
Endogenous glucose production (Study I)
Endogenous glucose production (EGP) was measured in the RISC study with [6-
62H2] glucose in the fasting state and during the euglycemic–hyperinsulinemic
clamp. A primed continuous infusion of labelled glucose was continued for 2 h and
blood samples obtained during the last 20 min of the equilibration period to measure
the plasma tracer concentration. EGP during the clamp was measured assuming a
monocompartment model for glucose kinetics. Insulin sensitivity was measured by
the euglycemic insulin clamp technique [259], using a primed infusion rate of 1
mUmin1kg1, followed by an exogenous glucose infusion.
Oral glucose tolerance test
A 2 h OGTT (75 g glucose) was performed after an overnight fast and samples for
plasma glucose, insulin and NEFA were drawn at 0, 30 and 120 min.
Laboratory measurements
The plasma glucose concentration was measured by the glucose oxidase method in
the  EGIR-RISC  study  and  by  the  enzymatic  hexokinase  photometric  assay  in
METSIM study. Plasma insulin and proinsulin concentrations were measured by
radioimmunoassay. Body composition was determined by bioelectrical impedance.
Glucagon levels were measured by glucagon assay (developed in J. Holst’s
laboratory, University of Copenhagen, Denmark) and NEFA by spectrophotometry
in RISC study and colorimetry in METSIM study. Total cholesterol, LDL cholesterol,
HDL cholesterol, total triglycerides and alanine aminotransferase (ALT) were
measured by standard colorimetric methods. Blood pressure (BP) was measured in
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the sitting position after a 5-minute rest with a mercury sphygmomanometer. The
average of 3 measurements was used to calculate systolic and diastolic BP. Plasma
adiponectin was measured by an enzyme immunoassay method (Human
Adiponectin Elisa Kit, Linco Research, St Charles, Mi, USA), apolipoprotein B by
immunoturbidimetry (Konelab Systems Reagents). Serum concentrations of high-
sensitivity C-reactive protein (hs-CRP) were assayed by Kinetic
immunoturbidimetry (Immage Immunochemistry System, Beckman Coulter, CA,
USA).
Genotyping
Genotyping of SNPs (PPARG2 rs1801282, KCNJ11 rs5219, TCF7L2 rs7903146,
SLC30A8 rs13266634, HHEX rs1111875, rs7480010 [previously assigned to gene locus
LOC387761], CDKN2B rs10811661, IGF2BP2 rs4402960, CDKAL1 rs7754840, HNF1B
rs7501939, WFS1 rs10010131, JAZF1 rs864745, CDC123 rs12779790, TSPAN8
rs7961581, THADA rs7578597, ADAMTS9 rs4607103, NOTCH2 rs10923931, KCNQ1
rs2283228) was performed with the TaqMan Allelic Discrimination Assay (Applied
Biosystems,  Foster  City,  CA,  USA)  and  Sequenom  iPlex  Gold  SBE  assay  (for
MTNR1B rs10830963, ADRA2A rs10885122, FAM148A rs11071657, CRY2 rs11605924,
ADCY5 rs11708067, SLC2A2 rs11920090, FADS1 rs174550, DGKB rs2191349, PROX1
rs340874, GCK rs4607517, G6PC2 rs560887, GLIS3 rs7034200, GCKR rs780094, MADD
rs7944584). The TaqMan genotyping call rate was 100%, with an error rate of 0% in
4.5% of DNA samples genotyped in duplicate. Sequenom iPlex call rate was 90.2-
96.9%, and error rate 0% among 4.2% of DNA samples genotyped in duplicate. All
SNPs were consistent with Hardy-Weinberg equilibrium (p>0.001).
Gene expression data
Tissue-specific expression data were obtained from Gene-Sapiens [260], version IST4,
which contains expression data from 15 liver and 16 adipose tissue samples from
healthy human tissue, measured with Affymetrix (Santa Clara, CA, USA) gene
expression microarrays. The following mean relative expression level values from
GeneSapiens were used to classify expression levels: <300 for low, 300 to 700 for
medium and >700 for high expression.
Liver histological analysis
Liver biopsies were performed using Tru-Cut (Radiplast, Uppsala, Sweden) during
the elective gastric bypass operation. Histological assessment of the liver was
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performed as described previously [261]. Steatosis was graded into four categories
(<5%, 5–32%, 33–66% and >66%).
Lipoprotein subclasses
Proton Nuclear Magnetic Resonance (NMR) spectroscopy was used to measure
lipid, lipoprotein subclass and particle concentrations in native serum samples as
previously described [262]. Total lipid and particle concentrations of 14 lipoprotein
subclasses were measured. The measurements of these subclasses have been
calibrated using high-performance liquid chromatography methods [263]. The
subclasses were as follows: chylomicrons and largest VLDL particles, five different
VLDL subclasses: very large VLDL, large VLDL, medium-size VLDL, small VLDL,
and very small VLDL; intermediate-density lipoprotein (IDL); three LDL subclasses:
large  LDL,  medium-size  LDL,  and  small  LDL.  The  following  components  of  the
lipoprotein particles were measured: phospholipids, triglycerides, cholesterol, free
cholesterol and cholesterol esters. In addition, mean particle diameters of VLDL and
LDL fractions were calculated on the basis of the corresponding subclass
distributions (IDL particles were included in the LDL fraction).
Calculations
The trapezoidal method was used to calculate glucose and insulin AUC in an OGTT
based on 0, 30 and 120 min data (AUC 0–120 min). The Liver IR index was calculated
from the formula: -0.091 + (log insulin AUC 0-120 min × 0.400) + (log fat mass % ×
0.346) - (log HDL Cholesterol × 0.408) + (log BMI × 0.435). The hepatic insulin
resistance index proposed by Abdul-Ghani et al. was calculated as described [264].
The adipocyte IR index was calculated as a product of fasting NEFA and fasting
insulin, Ins0 × NEFA0, as previously reported [265]. HOMA-IR and Matsuda ISI were
calculated as described earlier [266,267]. A combined genetic risk score for liver IR
was calculated as the sum of type 2 diabetes risk alleles at five SNPs that were
significantly or nominally associated (after adjustment for age, BMI and WHR) with
Liver IR index (at KCNJ11, HHEX, CDKN2B, NOTCH2 and MTNR1B loci), and were
weighted for their effect sizes.
For Study IV, early-phase insulin release during the first 30 min of an OGTT
(InsAUC0-30/GluAUC0-30), HOMA-B index of basal insulin secretion, and indices of
proinsulin conversion in the fasting state (Proins0/Ins0),  during  the  first  30  min
(ProinsAUC0-30/InsAUC0-30), 30 to 120 min (ProinsAUC30-120/InsAUC30-120), and 0 to 120
min (ProinsAUC0-120/InsAUC0-120) of an OGTT were calculated as reported previously
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[268]. Disposition index was calculated as InsAUC0-30/GluAUC0-30 ×  Matsuda  ISI.  A
genetic risk score was calculated as a sum of FG-increasing alleles associated (p<0.05)
with a trait weighted for their effect sizes for each trait individually.
Statistical analysis
Pearson correlation analysis was performed between EGP×FPI and all clinical and
laboratory variables such as glucose and insulin AUC from an OGTT, fasting NEFA,
lipoproteins, measures of adiposity, alanine transaminase, adiponectin and glucagon
(for Study I) and between Liver IR index and Matsuda ISI with CVD risk factors (for
Study III). Test of equality of correlations was based on Fisher’s r to z-transformation
where each correlation coefficient was converted into a z-score and compared taking
into account the sample size. Forward multiple stepwise regression analysis was
applied to identify the statistically significant determinants of EGP×FPI. The effect of
sex and obesity on Liver IR index was tested using a univariate linear regression
model.
In Study II, changes in indices across the categories of glucose levels were estimated
by general linear model adjusted for age, BMI and WHR. Associations between
SNPs and continuous traits were presented as effect sizes ( and SE) per copy of the
type 2 diabetes risk allele, estimated by linear regression adjusted primarily for age,
and additionally for age, BMI and WHR.
In order to examine the variance of different CVD risk factors explained by the Liver
IR index and Matsuda ISI in Study III, the coefficient of determination (adjusted R2)
for CVD risk factors was calculated from linear regression adjusted for age.
In Study IV, the effect of the genetic risk score (GRS) on Proins0/Ins0 and ProinsAUC0-
30/InsAUC0-30 ratios was analyzed by linear regression adjusted for age, BMI, and
Matsuda ISI. Hardy-Weinberg equilibrium was tested by 2-test. In all of the above
studies, the variables were log-transformed to correct for their skewed distribution,
except for Liver IR index, total cholesterol and LDL cholesterol that were normally
distributed. Statistical power calculations were performed using Bioconductor’s
GeneticsDesign package version 1.14 [269]. p<0.05 was considered nominally
significant in all studies. The thresholds for statistical significance after correction for
multiple testing in each of the studies were as follows: p<0.0013 (Study II), p<0.0019
(Study III) and p<8.68x10-5 (Study IV).
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5. Results
5.1 A NOVEL SURROGATE INDEX FOR HEPATIC INSULIN
RESISTANCE (Study I)
Baseline characteristics. The  study  sample  included  in  this  analyses  comprised  of
368 clinically healthy non-diabetic men and women from the RISC study (183 males;
age 43±8.22; BMI 25.94±3.95), wherein a total of 288 subjects had normal glucose
tolerance and 80 either impaired fasting glucose, impaired glucose tolerance, or both
as per the ADA criteria.
Validation of Liver IR index. Correlation analyses were performed between
EGPxFPI and all  clinical and laboratory variables such as glucose and insulin AUC
from an OGTT, fasting NEFA, lipoproteins, measures of adiposity, alanine
transaminase, adiponectin and glucagon. Variables having correlation (r) of r0.2
with EGP×FPI, including BMI, waist, fat mass %, HDL cholesterol, total triglycerides,
adiponectin, glucose AUC 0-120 min, insulin AUC 0-120 min, were included in the
multiple stepwise linear regression analysis. Four of these variables remained
statistically significant in the regression model and were used to develop a novel
surrogate marker of hepatic insulin resistance, Liver IR index as follows.
Liver IR index = -0.091 + (log Insulin AUC 0-120 × 0.400) +
(log fat mass % × 0.346) - (log HDL cholesterol × 0.408) + (log BMI ×
0.435)
Liver IR index correlated significantly with EGP×FPI (r=0.65, p<0.001)
38
Figure 6. Pearson correlation of Liver IR index with endogenous glucose production
(EGP) multiplied by fasting plasma insulin (FPI) (r=0.65, p<0.001)
Liver IR index exhibited a slightly stronger correlation with EGP×FPI in
glucose intolerant subjects (r=0.69) than in normoglycemic subjects (r=0.62). Liver IR
index correlated strongly in obese subjects (BMI>25, n=206, r=0.62, p<0.001) than in
lean subjects (BMI25, n=162, r=0.53, p<0.001).
The correlation of Liver IR index with EGPxFPI was similar when
compared with basal EGP and EGP during clamp. The correlation coefficients of the
Liver IR index with EGP×FPI were similar for men and women (r=0.65).
5.2 ASSOCIATION OF SNPs ASSOCIATED WITH THE RISK OF TYPE
2 DIABETES WITH LIVER AND ADIPOSE TISSUE-SPECIFIC
INSULIN RESISTANCE (Study II)
Baseline characteristics. Among the 8,460 non-diabetic subjects examined in this
study, a total of 2,951 subjects had normal glucose tolerance, 4,181 isolated IFG, 302
isolated IGT, and 1,026 both IFG and IGT according to the ADA criteria.
Association of Liver IR and Adipocyte IR indices with glucose levels. Liver IR
index  was  significantly  associated  with  both  FPG  (increase  up  to  1.4%)  and  2hPG
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levels (increase up to 3.5%), p=3.1×10-12 and 5.4×10-103, respectively. Similarly,
Adipocyte IR index also showed a significant association with both FPG (increase up
to +88%) and 2hPG (increase up to +108%), p=2.9×10-122 and 1.0×10-219, respectively.
Figure 7. Liver IR (a,b) and Adipocyte IR (c,d) indices across the categories of fasting
(FPG) and 2-hour plasma glucose (2hPG) levels within the non-diabetic range. Bars
display  values  relative  to  the  reference  category  (FPG  <  5.0  mmol/l,  2hPG  <  5.0
mmol/l).  White  bars  indicate  normal  glucose  levels  (NFG  and  NGT)  and  grey  bars
indicate  impaired  glucose  levels  (IFG  and  IGT).  Calculations  were  based  on  geometric
means, adjusted for age, BMI and WHR with the general linear model and p values were
obtained as follows: (a)3.1×10-12, (b)5.4×10-103, (c)2.9×10-122 and (d)1.0×10-219
Association of type 2 diabetes SNPs with Liver IR index. HHEX rs1111875 and
MTNR1B rs10830963 were significantly and four other SNPs (at KCNJ11, TCF7L2,
CDC123 and NOTCH2 loci) nominally associated with Liver IR index in analyses
adjusted for age only. When additional adjustments were done for BMI and WHR,
risk alleles at five SNPs decreased Liver IR either significantly, HHEX rs1111875
(p=5.4×10-5) and KCNJ11 rs5219 (p=1.8×10-4), or nominally, CDKN2B rs10811661
(p=0.013), NOTCH2 rs10923931 (p=0.016) and MTNR1B rs10830963 (p=0.009). The
Pro12 allele (rs1801282) of PPARG2 was associated with a higher Liver IR (p=0.039).
All effect sizes were less than 0.3% per risk allele.
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Table 3. Association of 19 SNPs with Liver IR index in 6,733 non-diabetic men
Gene   SNP Allele MAF%
Liver IR index
Expression
in liver
adjusted for age only adjusted for age, BMI and WHR
 SE p value  SE % p value
PPARG2 rs1801282 Ca/G 15.3 -0.0001 0.004 0.981 0.006 0.003 0.21 0.039 Low
KCNJ11 rs5219 G/Aa 47.4 -0.009 0.003 0.002 -0.008 0.002 -0.27 1.8E-04 Low
TCF7L2 rs7903146 C/Ta 17.5 -0.008 0.004 0.034 -0.004 0.003 -0.16 0.090 High
SLC30A8 rs13266634 Ca/T 39.3 -0.003 0.003 0.359 0.0003 0.002 0.01 0.879 Low
HHEX rs1111875 Ca/T 46.6 -0.010 0.003 3.5E-04 -0.008 0.002 -0.29 5.4E-05 High
rs7480010 A/Ga 17.4 -0.007 0.004 0.083 -0.003 0.003 -0.10 0.288 -
CDKN2B rs10811661 Aa/G 14.8 -0.005 0.004 0.191 -0.007 0.003 -0.25 0.013 Low
IGF2BP2 rs4402960 C/Aa 32.0 -0.002 0.003 0.529 -0.001 0.002 -0.04 0.600 Low
CDKAL1 rs7754840 G/Ca 36.9 -0.006 0.003 0.053 -0.003 0.002 -0.12 0.125 Low
WFS1 rs10010131 Ga/A  44.6 -0.002 0.003 0.567 -0.001 0.002 -0.05 0.465 Medium
HNF1B rs7501939 C/Ta 27.3 0.004 0.003 0.173 -0.0003 0.002 -0.01 0.865 High
JAZF1 rs864745 Aa/G  48.4 0.004 0.003 0.192 0.004 0.002 0.14 0.054 Low
CDC123 rs12779790 A/Ga 21.3 -0.007 0.003 0.034 -0.003 0.002 -0.11 0.212 High
TSPAN8 rs7961581 A/Ga 19.9 -0.001 0.004 0.864 0.003 0.003 0.10 0.282 Medium
THADA rs7578597 Aa/G   5.1 -0.005 0.007 0.427 -0.007 0.005 -0.24 0.142 Medium
ADAMTS9 rs4607103 Ga/A  25.8 -0.001 0.003 0.792 -0.001 0.002 -0.04 0.600 Medium
NOTCH2 rs10923931 C/Aa 14.0 -0.009 0.004 0.023 -0.007 0.003 -0.26 0.016 Medium
KCNQ1 rs2283228 Aa/C 6.1 -0.002 0.006 0.785 -0.002 0.004 -0.06 0.704 Low
MTNR1B rs10830963 C/Ga 35.8 -0.010 0.003 0.001 -0.005 0.002 -0.20 0.009 Low
Effect  sizes ( and SE and % of   from mean) and corresponding p values per type 2
diabetes risk allele are shown. Results for the additive model are presented based on
adjustments as indicated. Tissue-specific expression of respective genes was obtained
from GeneSapiens database [260] a type 2 diabetes risk allele.
Further analyses revealed that additional adjustment for insulin secretion (InsAUC0-
30/GluAUC0-30)  abolished  the  associations  of PPARG, KCNJ11, and NOTCH2 with
Liver  IR,  and  weakened  the  association  of HHEX with  Liver  IR  (p=0.003) to a
nominally significant level.
Combined effect of risk alleles on Liver IR index. The risk alleles of 5 SNPs that
significantly  or  nominally  reduced  Liver  IR  (KCNJ11 rs5219, HHEX rs1111875,
CDKN2B rs10811661, NOTCH2 rs10923931 and MTNR1B rs10830963) in adjusted
analyses were combined to evaluate their joint effects. There was a small but
consistent decrease, up to 2% (p=6.9×10-9), in the Liver IR with an increasing number
of risk alleles.
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Figure 8. Liver IR index according to the number of type 2 diabetes risk alleles combined
for  five  SNPs  (KCNJ11 rs5219, HHEX rs1111875, CDKN2B rs10811661, NOTCH2
rs10923931 and MTNR1B rs10830963). Data are adjusted for age, BMI and WHR. Black
circles with error bars indicate means and SE; grey bars show the number of participants
in  each  category.  The  effect  of  the  number  of  risk  alleles  on  Liver  IR  index  was
significant (p = 6.9x10-9)
Association of type 2 diabetes SNPs with Adipocyte IR index. PPARG2 rs1801282,
TCF7L2 rs7903146 and NOTCH2 rs10923931 (p=0.026, 0.038 and 0.044, respectively)
showed nominally significant association with adipocyte IR index when adjusted for
age only. Additional adjustment for BMI and WHR strengthened the association of
the Pro12 allele of PPARG2 with  higher  adipocyte  IR  index  (p=6.2×10-5, effect size
+7% per allele) to a significant level, and abolished the other associations.
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Table 4. Association of 19 SNPs with Adipocyte IR index in 6,733 non-diabetic men
Gene   SNP Allele MAF%
Adipocyte IR index Expression
in adipose
tissue
adjusted for age only adjusted for age, BMI and WHR
 SE p value  SE % p value
PPARG2 rs1801282 Ca/G 15.3 0.824 0.402 0.026 1.226 0.349 6.58 6.2E-05 High
KCNJ11 rs5219 G/Aa 47.4 -0.634 0.290 0.081 -0.517 0.251 -2.77 0.124 Low
TCF7L2 rs7903146 C/Ta 17.5 -0.582 0.377 0.038 -0.344 0.327 -1.85 0.089 High
SLC30A8 rs13266634 Ca/T 39.3 -0.498 0.295 0.080 -0.300 0.256 -1.61 0.213 Low
HHEX rs1111875 Ca/T 46.6 -0.559 0.287 0.098 -0.426 0.249 -2.29 0.169 High
rs7480010 A/Ga 17.4 -0.896 0.383 0.071 -0.602 0.332 -3.23 0.236 -
CDKN2B rs10811661 Aa/G 14.8 0.736 0.407 0.384 0.614 0.353 3.29 0.482 Low
IGF2BP2 rs4402960 C/Aa 32.0 -0.462 0.307 0.310 -0.419 0.266 -2.25 0.278 Low
CDKAL1 rs7754840 G/Ca 36.9 -0.233 0.299 0.119 -0.021 0.259 -0.11 0.361 Low
WFS1 rs10010131 Ga/A 44.6 -0.495 0.289 0.297 -0.483 0.25 -2.59 0.224 High
HNF1B rs7501939 C/Ta 27.3 0.241 0.333 0.510 -0.100 0.289 -0.54 0.546 Medium
JAZF1 rs864745 Aa/G 48.4 0.247 0.286 0.126 0.233 0.248 1.25 0.076 Medium
CDC123 rs12779790 A/Ga 21.3 -0.490 0.350 0.231 -0.194 0.304 -1.04 0.730 High
TSPAN8 rs7961581 A/Ga 19.9 -0.319 0.361 0.767 -0.075 0.312 -0.40 0.614 Low
THADA rs7578597 Aa/G 5.1 -0.111 0.657 0.960 -0.217 0.569 -1.16 0.907 Medium
ADAMTS9 rs4607103 Ga/A 25.8 -0.475 0.332 0.168 -0.518 0.288 -2.78 0.075 Medium
NOTCH2 rs10923931 C/Aa 14.0 -0.937 0.418 0.044 -0.771 0.362 -4.14 0.063 High
KCNQ1 rs2283228 Aa/C 6.1 -0.079 0.600 0.861 -0.126 0.519 -0.68 0.762 Low
MTNR1B rs10830963 C/Ga 35.8 -0.435 0.299 0.212 -0.162 0.259 -0.87 0.795 Low
Effect  sizes ( and SE and % of   from mean) and corresponding p values per type 2
diabetes-risk allele (underlined) are shown. Results for the additive model are presented
based on adjustments as indicated. p values for Adipocyte IR index were calculated
using log-transformed variable due to its skewed distribution. Tissue-specific expression
of  the  respective  genes  was  obtained  from  GeneSapiens  database  [260]. a type  2
diabetes risk allele.
5.3 LIVER INSULIN RESISTANCE AND CARDIOVASCULAR RISK
FACTORS (Study III)
Baseline characteristics. Among 8,750 non-diabetic men included in the analyses
from the Metabolic Syndrome In Men (METSIM) Study, a total of 3,034 (34.7%) men
had NGT, 4,345 (49.7%) had isolated IFG, 312 (3.6%) had isolated IGT and 1,059
(12.1%) had IFG and IGT, according to the ADA criteria.
Correlations of Liver IR index and Matsuda ISI with CVD risk factors. Liver IR
index and Matsuda ISI correlated significantly (p<0.0019) with all CVD risk factors
examined except for LDL cholesterol (both indices), and total cholesterol (Matsuda
ISI). Liver IR index correlated significantly more strongly than Matsuda ISI with age
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(r=0.161 vs. -0.067), total cholesterol (r=-0.088 vs. 0.020), hs-CRP (r=0.284 vs. -0.219),
and total triglycerides (r=0.507 vs. -0.477, nominally significant difference p<0.05). In
contrast, compared to Liver IR index, Matsuda ISI showed nominally stronger
correlations with systolic and diastolic BP (r=-0.234 and -0.275 vs. r=0.202 and 0.239,
respectively).
Table 5. Pearson correlation coefficients of Liver IR index and Matsuda ISI with various
CVD risk factor levels in non-diabetic men
CVD risk factor
  Liver IR index Matsuda ISI
Pcomp
r p value r p value
Age 0.161 <1×10-6 -0.067 <1×10-6 <1×10-6
Systolic Blood Pressure 0.202 <1×10-6 -0.234 <1×10-6 0.027
Diastolic Blood Pressure 0.239 <1×10-6 -0.275 <1×10-6 0.011
Total cholesterol -0.088 <1×10-6 0.020 0.066 <1×10-6
LDL cholesterol 0.011 0.297 -0.012 0.269 0.947
Total triglycerides 0.507 <1×10-6 -0.477 <1×10-6 0.009
Apolipoprotein B 0.251 <1×10-6 -0.230 <1×10-6 0.142
C-reactive protein 0.284 <1×10-6 -0.219 <1×10-6 <1×10-6
Plasma adiponectin -0.340 <1×10-6 0.338 <1×10-6 0.882
Pearson correlation coefficients r and the corresponding p values of  Liver IR index and
Matsuda  ISI  with  CVD risk  factor  levels  are  shown. Pcomp represents p value indicating
the difference between the two correlation coefficients.
Extent of variance of the CVD risk factors explained by Liver IR index and
Matsuda ISI. The coefficient of determination, R2, obtained from linear regression
analyses to examine the extent of variance of CVD risk factors explained by both
indices demonstrated that the Liver IR index explained more variance for the
majority of CVD risk factors than did Matsuda ISI. The age-adjusted variance
explained by Liver IR index was largest for total triglycerides (28%), whereas the
corresponding percentage for Matsuda ISI was 24%. In order to determine the
variance explained by the Liver IR index, independent of Matsuda ISI, both variables
were included in the same model. These analyses revealed that the variance
explained increased when Liver IR index was additionally included with Matsuda
ISI in the model. Furthermore, the percent variance based on the R2 change,
including both the indices, indicated that Liver IR index explained a substantially
higher proportion of the variation of total triglycerides, plasma adiponectin (11.6 vs.
0.2%), hs-CRP (8.1 vs. 0.6%) and apolipoprotein B (6.3 vs. 0.1%) than did Matsuda ISI.
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Table 6. Variance of cardiovascular (CVD) risk factors explained by Liver IR index and
Matsuda ISI in non-diabetic subjects
CVD risk factor
Liver IR index
adjusted for age
Matsuda ISI
adjusted for age
Liver IR index adjusted for
age and Matsuda ISI
R2 p value PV R2 p value PV R2 p value PV*
Systolic Blood Pressure 0.090 <1×10-6 4.1 0.110 <1×10-6 5.5 0.116 <1×10-6 0.5/4.8
Diastolic Blood Pressure 0.080 <1×10-6 5.7 0.093 <1×10-6 7.5 0.093 0.102 -/7.6
Total cholesterol 0.027 <1×10-6 0.8 0.023 0.364 - 0.038 <1×10-6 2.7/1.1
LDL cholesterol 0.029 0.0003 - 0.028 0.029 - 0.029 0.0002 0.1/-
Total triglycerides 0.284 <1×10-6 25.7 0.240 <1×10-6 22.7 0.285 <1×10-6 25.7/0.1
Apolipoprotein B 0.114 <1×10-6 6.3 0.092 <1×10-6 5.3 0.115 <1×10-6 6.3/0.1
hs-C reactive protein 0.080 <1×10-6 8.0 0.050 <1×10-6 4.8 0.086 <1×10-6 8.1/0.6
Plasma adiponectin 0.151 <1×10-6 11.6 0.138 <1×10-6 11.4 0.153 <1×10-6 11.6/0.2
Adjusted  R  squared  (R2) and P values obtained from linear regression analyses using
CVD risk factor as dependent variable and independent variables as indicated. PV
indicates  percent  variance  of  the  CVD  risk  factor  explained  by  the  respective  indices
alone. PV* indicates the individual contribution of Liver IR index/Matsuda ISI, when both
were included in the model together. (The percent variance is based on the R-squared
change).  ‘-‘  indicates  that  the  respective  index  was  not  significant  in  the  model
(indicating that in such cases, age alone explained a larger variation).
5.4 ASSOCIATION OF SNPs INCREASING FASTING GLUCOSE WITH
INDICES OF INSULIN RELEASE, PROINSULIN CONVERSION AND
INSULIN SENSITIVITY (Study IV)
The association of 16 SNPs with InsAUC0-30/GluAUC0-30 as an index of insulin release,
Matsuda ISI as a measure for insulin sensitivity, disposition index and Proins0/Ins0 as
an index for proinsulin processing were as follows.
Association with insulin release (Table 7). FG-increasing alleles at 8 SNPs (in or
near CRY2, DGKB, FADS1, GCK, GCKR, MTNR1B, SLC30A8, and TCF7L2) were
associated with the lower InsAUC0-30/GluAUC0-30 index of early-phase insulin release.
Associations of MTNR1B and TCF7L2 remained significant after correction for
multiple testing and adjustment for BMI and Matsuda ISI in addition to age (effect
sizes -6.5 and -4.2% per FG-increasing allele). Associations of CRY2, FADS1 and GCK
with insulin release were nominally significant after adjustments and SLC30A8
persisted before and after adjustments (effect size magnitudes <5%), whereas
associations of DGKB and GCKR disappeared after adjustment for Matsuda ISI
(adjustment for BMI did not affect the association, data not shown). FG-increasing
alleles at 13 SNPs (ADRA2A, ADCY5, CRY2, DGKB, FADS1, GCK, GLIS3, G6PC2,
MADD, MTNR1B, SLC2A2, SLC30A8, TCF7L2) were associated with lower HOMA-B
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index of basal insulin secretion after adjustment for age, BMI and Matsuda ISI. The
effects of DGKB, G6PC2 and MTNR1B remained significant after correction for
multiple testing (effect sizes 4-6% per FG-increasing allele).
Association with insulin sensitivity (Table 7). A nominal association for GCKR
rs780094, with an effect size of -2.6% in Matsuda ISI per FG-increasing allele was
observed among the 16 SNPs examined.
Association with Disposition index (Table 7). Six SNPs associated with lower
disposition index (CRY2, FADS1, GCK, MTNR1B, SLC30A8, TCF7L2). Only
association of MTNR1B remained significant after correction for multiple testing,
with effect size of 6.6 per FG-increasing allele (adjusted for age and BMI).
Association with proinsulin conversion (Table 7). FG-increasing alleles at 3 SNPs
(MADD, SLC30A8, and TCF7L2) were significantly and consistently associated with
the higher proinsulin/insulin ratio in the fasting state (Proins0/Ins0) and similarly in
the glucose-stimulated state (not shown here). MADD showed the most prominent
associations, with effect sizes of 7-10% per allele. The FG-increasing allele at the
GCKR locus was nominally associated with a lower proinsulin/insulin ratio in the
fasting state and during an OGTT (all indices) although this effect weakened after
adjustment for Matsuda ISI, suggesting a possible compensatory change tin response
to insulin resistance rather than a causal effect. Furthermore, adjustment for BMI and
Matsuda ISI revealed nominal associations of ADCY5 and GLIS3 loci with
Proins0/Ins0.
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Association with fasting glucose (Table 8). Eleven SNPs (in or near ADCY5, CRY2,
DGKB, FADS1, GCK, GCKR, G6PC2, MTNR1B, SLC2A2, SLC30A8, TCF7L2) were
associated with higher FG levels, although only associations of G6PC2 and MTNR1B
remained statistically significant after correction for multiple testing. Adjustment for
age and BMI did not affect the results. The effect sizes were modest with MTNR1B
showing the largest effect (0.088 mmol/l or 1.5% increase in FG per risk allele).
Table 8. Association of 16 SNPs with fasting glucose levels in 8,750 non-diabetic Finnish
men
Fasting glucose (mmol/l)
Gene locus,  SNP Alleles EAF Effect size
(%)  SE P P *
ADCY5 rs11708067 A/G 15.9 0.028 0.013 0.034 0.038
ADRA2A rs10885122 G/T 15.5 0.021 0.014 0.105 0.098
CRY2 rs11605924 A/C 46.9 0.031 0.010 0.004 0.010
DGKB rs2191349 G/T 43.1 0.031 0.010 0.002 0.001
FADS1 rs174550 T/C 42.8 0.025 0.010 0.012 0.004
FAM148A rs11071657 A/G 30.5 0.010 0.011 0.280 0.319
GCK rs4607517 G/A 9.8 0.055 0.016 0.001 0.001
GCKR rs780094 C/T 37.7 0.029 0.010 0.004 0.002
GLIS3 rs7034200 C/A 48.8 0.018 0.010 0.057 0.068
G6PC2 rs560887 C/T 27.8 0.071 0.011 3.5E-11 1.9E-12
MADD rs7944584 A/T 18.0 0.022 0.013 0.094 0.108
MTNR1B rs10830963 C/G 35.8 0.088 0.009 5.1E-24 2.6E-27
PROX1 rs340874 T/C 39.7 0.011 0.010 0.277 0.318
SLC2A2 rs11920090 T/A 13.1 0.034 0.015 0.017 0.019
SLC30A8 rs13266634 C/T 39.3 0.027 0.009 0.001 2.7E-04
TCF7L2 rs7903146 C/T 17.5 0.027 0.011 0.016 0.004
Effect size shown is -coefficient (SE) per copy of fasting glucose increasing allele
(underlined),  and  was  calculated  by  linear  regression  adjusted  for  age. P values were
adjusted for age, P* values were adjusted for age and BMI. In the entire cohort,
meanSE of fasting glucose was 5.700.48. Nominally significant P values (P<0.05) are
in bold, P values significant after correction for multiple testing (P<8.68x10-5) are in bold
and underlined. Results for the additive model are presented. EAF – effect allele
frequency.
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Analysis of traits according to the genetic risk scores (Figure 9). By combining the
risk alleles at SNPs, nominally or significantly associated with the trait of interest, a
GRS for each individual trait was calculated. An increasing number of FG-increasing
alleles was associated with a gradual decrease in InsAUC0-30/GluAUC0-30, HOMA-B
and the disposition index by 20, 24 and 24%, respectively, in carriers with the largest
number  of  risk  alleles.  Although  the  effects  of  the  GRS  on  basal  and  glucose-
stimulated insulin secretion were comparable, the increase in the proinsulin/insulin
ratio during an OGTT (ProinsAUC0-30/InsAUC0-30)  was considerably larger than that
in the fasting state (42 vs. 27%). In contrast, the GRS had only a rather modest effect
on the FG level (a 7% increase in the carriers of 	19 risk alleles compared with the
carriers of 8 risk alleles at 11 SNPs).
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Figure  9.  Combined  effects  of  associated  (P<0.05) SNPs on the glucose- and insulin-
related traits as follows: A –  early-phase  insulin  release  (InsAUC0-30/GluAUC0-30), B –
basal insulin secretion (HOMA-B), C – Disposition index, D - index of proinsulin-to-insulin
conversion at fasting state (Proins0/Ins0), E - index of proinsulin-to-insulin conversion
during 0-30 min of an OGTT (ProinsAUC0-30/InsAUC0-30), F – fasting glucose. Genetic risk
scores were calculated as the number of FG-increasing (risk) alleles in SNPs associated
(P<0.05) with the respective trait weighted for their effect sizes. Filled circles display the
value of the respective trait relative to the reference category with the lowest number of
risk  alleles.  Calculations  were  based  on  geometric  means,  adjusted  for  age,  BMI,
(Matsuda ISI) with the general linear model. Bars show the numbers of subjects in each
category.
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6. Discussion
6.1 REPRESENTATIVENESS OF THE STUDY SUBJECTS
The study involved two well-characterized and large study samples 1) the European
Group  for  the  study  of  Insulin  Resistance-Relationship  between  Insulin  Sensitivity
and Cardiovascular disease (EGIR-RISC) study 2) the Metabolic Syndrome In Men
(METSIM) study.
Study I included 368 healthy subjects from the EGIR-RISC study cohort.
The study includes data pooled from euglycemic hyperinsulinemic clamp
experiments performed in 21 centres across Europe which makes it one of the largest
database available with clamp data. Baseline measurements of glucose tolerance and
insulin sensitivity were performed by an OGTT and the euglycemic insulin clamp. In
this study, hepatic insulin resistance was measured by using the glucose tracer
technique (tritiated glucose) and calculated as the product of endogenous glucose
production  and  fasting  plasma  insulin  (EGPxFPI),  considered  to  be  the  gold-
standard measure. Measurement of hepatic insulin resistance with the most accurate
gold-standard method in this study was ideal towards achieving our objective of
developing a novel surrogate index for assessing insulin resistance in the liver. One
limitation of the study is that though it includes data from different centers, they are
all of European origin, therefore the genetic differences in the participants are likely
to be small.
Studies II – IV included >6700 Finnish middle-aged non-diabetic subjects
from the Kuopio region who were participants in the METSIM study. The study
population has been well-characterised and the subjects were carefully phenotyped.
Baseline measurements of glucose tolerance and insulin sensitivity were measured
by  an  OGTT.  Measurement  of  insulin  sensitivity  with  glucose  clamp,  the  gold-
standard method was not feasible, owing to the large sample size. However, the
OGTT-derived indices employed in the study have been validated and are being
used in several studies. Furthermore, most of the reported genetic
variants/polymorphisms related to type 2 diabetes have been genotyped in the entire
study population. The effects of genetic variants on type 2 diabetes were modest.
The effects of risk loci on insulin sensitivity were not as strong as their effects on
insulin secretion. One of the limitations of the study is the inclusion of only men.
However, no consistent differences have been reported between men and women in
terms of genetic associations.
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6.2 HEPATIC INSULIN RESISTANCE (Studies I-II)
The inability of insulin to suppress endogenous glucose production (EGP) and to
promote glucose uptake is a major metabolic consequence of insulin resistance in the
liver. As the diabetic state worsens, an increase in basal hepatic glucose production
and/or its decreased suppression by insulin are the major factors responsible for a
progressive rise in the fasting glucose levels.
A linear relationship exists between the rise of the fasting plasma insulin
(FPI) level and the decline in the rate of basal EGP in healthy subjects. Endogenous
glucose production primarily reflects hepatic glucose production as >80% of it
originates in the liver [270]. Thus, the higher the rate of EGP and the level of FPI, the
greater is the severity of hepatic insulin resistance. Based on the above principle, the
concomitant use of isotopes in clamp studies has revealed that hepatic glucose
production is insufficiently inhibited by insulin, demonstrating the presence of
insulin resistance in the liver and therefore, a product of endogenous glucose
production and fasting plasma insulin (EGPxFPI) is widely accepted as the golden
standard measure for hepatic insulin resistance [259].
6.2.1 Development of Liver IR index (Study I)
We developed a novel surrogate marker, Liver IR index, for hepatic insulin
resistance that correlated strongly with EGPxFPI. Unlike other markers that are
based mainly on OGTT-derived measures of glucose and insulin, this index takes
into consideration various metabolic traits that are related to hepatic insulin
resistance, e.g. BMI, fatmass and HDL cholesterol. Obesity is a known risk factor for
hepatic insulin resistance. Moreover, intra-abdominal visceral fat and abdominal
subcutaneous fat also correlate positively with hepatic insulin resistance [271].
Increased BMI and fatmass elevate the NEFA levels that directly promote liver
insulin resistance. Hepatic insulin resistance has also been described to reduce the
HDL cholesterol level [272]. Furthermore, it has been reported in a large study
involving non-diabetic subjects that estimates of obesity (BMI and waist
circumference) and dyslipidemia (TG/HDL-C ratio) are associated with features of
liver  disease  e.g.,  non-alcoholic  fatty  liver  disease  (NAFLD),  where  liver  insulin
resistance is a characteristic feature [273].
Previously only one study reported a surrogate marker specific for liver
insulin resistance [264]. It was calculated as product of glucose and insulin AUCs
during 0-30 min. However, the index showed a lower correlation (r=0.58, p<0.001)
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when compared to  the  Liver  IR index (r=0.65, p<0.001) in  our  study.  Moreover,  the
reported index was based on a study population that included mainly obese
individuals.
Therefore, in this study a novel surrogate index for hepatic insulin
resistance was developed and it was found to correlate well with the gold standard
measure in non-diabetic subjects, irrespective of obesity and glucose tolerance status.
However,  further  studies  need  to  be  conducted  in  other  ethnic  groups  and  in
women.
6.2.2 Hyperglycemia and hepatic and adipocyte insulin resistance (Study II)
Since insulin resistance manifests itself in different tissues, some of the known type 2
diabetes risk variants could have tissue-specific effects on insulin action. Therefore,
the  Liver  IR index and additionally  a  previously  reported adipocyte  IR index [268]
were used to investigate hepatic and adipose tissue specific insulin resistance in the
current study.
Insulin resistance in the adipose tissue leads to an impairment in
insulin’s antilipolytic effect, contributing to an increased flux of NEFAs into the
circulation, which in turn stimulates gluconeogenesis, decreases glucose uptake,
induces hepatic and muscle IR, and impairs insulin secretion [274,275]. The
adipocyte insulin resistance index (product of fasting plasma NEFA and FPI) was
reported to be significantly increased in both IFG and IGT subjects as compared to
individuals with NGT [265]. The adipocyte IR index increased by 	88% with
increasing  FPG  and  2hPG  levels  within  the  nondiabetic  range  of  glycemia.  An
increased adipocyte IR index indicates a loss of the antilipolytic effect of insulin.
Insulin resistance in the liver results in impaired suppression of hepatic
glucose production, contributing to elevated glucose levels in fasting and
postprandial states [77,78]. Our observation of a gradual increase of the Liver IR
index by 1.4 to 3.5% with higher levels of FPG and 2hPG agrees with these findings.
These associations with FPG and 2hPG levels are evidence that these indices are
likely to be reliable indicators of IR in the liver and adipose tissue.
SNPs regulating liver insulin resistance
The type 2 diabetes risk allele, rs5219 of KCNJ11, was significantly associated with a
lower Liver IR index. Similar results have been reported in a study showing that
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homozygous carriers of the rs5219 risk allele of KCNJ11 displayed a ~40% increase in
hepatic insulin sensitivity as measured by the clamp and tracer infusion, in addition
to an insulin secretion defect [143]. A nominal association of this variant with
increased Matsuda ISI had been previously reported in our METSIM study [268].
Thus,  this  variant  might  influence  type 2  diabetes  risk  by altering insulin  secretion
and also liver insulin sensitivity.
The type 2 diabetes risk allele of HHEX also showed a significant
association with lower liver IR. There is only one study reporting the association of
HHEX rs1111875 with greater insulin sensitivity measured by Matsuda ISI [268]. The
mechanisms by which HHEX affects liver insulin sensitivity are unknown, but
hepatocyte nuclear factor 1 (HNF1) could be involved, as HHEX, which is
abundantly expressed in the liver, has been shown to directly activate HNF1 in
mammalian hepatocytes [276]. Furthermore, HHEX is required for the organogenesis
of the ventral pancreas, indicating that early developmental defects due to this gene
variant might be plausible [277].
Additionally, SNPs of MTNR1B, CDKN2B, NOTCH2 and PPARG2
showed nominally significant associations with the Liver IR index. In agreement
with our results, a different SNP of MTNR1B has been reported to be associated with
decreased HOMA-IR [278]. In contrast, a study based on the hyperinsulinemic-
euglycemic clamp showed that the MTNR1B risk  allele  reduced  suppression  of
hepatic glucose production, suggesting that it could be associated with hepatic IR
[279]. CDKN2B polymorphism rs10811661 has been recently reported to be
associated  with  insulin  release  but  not  with  insulin  sensitivity  as  measured  by
hyperinsulinemic euglycemic glucose clamp or OGTT [280]. There have been no
reports of an association of NOTCH2 rs10923931 with insulin sensitivity, however
both NOTCH2 and CDKN2B have a role in the development of the liver [281,282].
Combined  analyses  of  the  five  SNPs  in KCNJ11, HHEX, CDKN2B,
NOTCH2 and MTNR1B detected a significant decrease in the Liver IR index (2%),
although these SNPs individually had an effect size of <0.3%. In an earlier study, we
reported that SNPs in or near HHEX, CDKN2B, MTNR1B and KCNJ11 were
associated with lower glucose-stimulated insulin release and showed comparatively
larger effect sizes from 1.2% to 6.7% per risk allele [268]. We believe that the variants
of these genes primarily affect insulin secretion and that their effect on liver insulin
sensitivity is of less importance and might be a compensatory mechanism.
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The associations between risk SNPs and Liver IR index either lost their
statistical significance (KCNJ11, CDKN2B, NOTCH2)  or  weakened  (HHEX) when
adjusted for insulin secretion (in addition to age, BMI and WHR). Furthermore,
previous studies have shown that HNF1A mutation carriers who have MODY [283]
and carriers of the E1506K mutation of ABCC8 [284] display increased insulin
sensitivity, although they have a severe defect in insulin secretion. Another study
showed that high insulin sensitivity, evaluated by the euglycemic clamp, reflecting
mostly skeletal muscle insulin sensitivity, could protect against the detrimental effect
of several genes on insulin secretion [285].
Based on the above observations in conjunction with the results from
our study it was hypothesized that the increased liver insulin sensitivity conferred
by these risk alleles could be a mechanism to counterbalance the impaired insulin
secretion. However, these compensatory mechanisms might be effective only in the
non-diabetic range of glycemia, and fail when frank hyperglycemia develops.
SNPs regulating adipocyte insulin resistance
The Pro12Ala polymorphism of PPARG2 was significantly associated with a higher
adipocyte IR index. The Ala allele of rs1801282 has been previously shown to be
associated with insulin sensitivity [96,286,287]. The Ala isoform due to its lower
transactivation capacity may lead to less efficient stimulation of PPAR target genes
and predispose  to  lower  levels  of  adipose  tissue mass  accumulation,  which in  turn
may be responsible for improved insulin sensitivity. In contrast, the more common
proline allele (~85% frequency) is known to be associated with a modest (1.25-fold)
but statistically significant increase in the risk of diabetes.
PPAR is a nuclear factor regulating the transcription of various genes,
particularly adipose specific genes involved in adipocyte differentiation; it also
contributes to the regulation of NEFA metabolism by stimulating uptake, storage
and oxidation of NEFA in adipocytes [288]. Since the Pro12Ala polymorphism is
present only in PPARG2,  which  is  found  prominently  in  adipose  tissue  [289],  it  is
probable that this SNP exerts its effect on insulin sensitivity directly in adipose
tissue. Increased release of NEFA from insulin-resistant adipose tissue may further
impair insulin sensitivity in the liver and this might well explain its weak association
with Liver IR index.
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6.3 LIVER INSULIN RESISTANCE AND CVD RISK FACTORS (Study
III)
There is a significant crosstalk between the liver, muscle and adipose tissue and
various factors that affect cardiovascular health. Therefore, it is likely that the
pathophysiological state of these organs is reflected also in risk factors for CVD.
Under insulin resistant conditions, the metabolic imbalance causes abnormal
production of several hormones, cytokines, inflammatory factors etc. depending on
the respective tissue and adversely affects cardiovascular health.
The association of Liver IR index and Matsuda ISI with various CVD
risk factor levels was investigated systematically in a large population-based sample
of non-diabetic men. It was found that Liver IR index correlated more strongly with
total triglyceride levels than with Matsuda ISI, although the difference was only
nominally significant. Total triglyceride levels increased up to 110% across the
quintiles of Liver IR index (explaining 28% of variation) and decreased to -51%
across the quintiles of Matsuda ISI. A meta-analysis including 29 studies reported
that elevated triglyceride levels were associated with increased coronary heart
disease risk which supports our observation [290]. Another study reported that a
progressive increase in the incidence of major coronary events was associated with
progressively increased levels of fasting triglyceride levels over eight years of
follow-up [291]. However, there is still controversy on the causal role of total
triglycerides as a risk factor for CVD events.
Various inflammatory factors/adipokines that are CVD risk factors are
secreted directly from adipocytes and adipose tissue-derived macrophages. These in
turn contribute to inflammation and the increased synthesis of inflammatory
proteins, e.g. CRP in the liver. In agreement with these observations, it was noticed
that  hs-CRP  levels  correlated  more  closely  with  the  Liver  IR  index  than  with  the
Matsuda ISI, and that hs-CRP increased significantly (up to +104%) across the
quintiles of Liver IR index. A recent meta-analysis comprising >7 000 patients with
coronary heart disease events showed that subjects with hs-CRP in the upper tertile
had a 50% increased risk for the development of acute CVD events [292].
A larger change in adiponectin levels was observed across the quintiles
of Matsuda ISI than across the quintiles of Liver IR index (+53 vs. -36%) which is in
agreement with the studies indicating that hyperinsulinemia decreases adiponectin
levels [293]. Adiponectin might directly modify hepatic insulin sensitivity since a
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negative correlation has been reported between plasma adiponectin level and
endogenous glucose production [294].
Systolic and diastolic BP are important CVD risk factors often associated
with  insulin  resistance.  In  subjects  with  hypertension  the  major  site  of  insulin
resistance is in peripheral insulin sensitivity tissues (mainly in skeletal muscle) and
not in the liver [295], which could explain nominally stronger correlations of systolic
and diastolic BP with Matsuda ISI than with Liver IR index in the current study.
The conclusion drawn from Study III is that the Liver IR index correlates
more  strongly  with  the  majority  of  CVD  risk  factors  than  does  Matsuda  ISI  which
reflects  whole  body  insulin  sensitivity.  Therefore,  it  is  likely  that  insulin  resistance
especially in the liver plays a major role in the adverse changes in CVD risk factors,
particularly those related to dyslipidemia and inflammation.
6.4 EFFECTS OF SNPS ELEVATING GLUCOSE ON INSULIN
SECRETION AND INSULIN SENSITIVITY (Study IV)
Fasting hyperglycemia is one of the hallmarks of liver insulin resistance and type 2
diabetes. To investigate the mechanisms underlying the elevation of fasting glucose
by the reported FG-elevating SNPs, we tested the association of these SNPs with
various indices of insulin secretion and insulin sensitivity. We found that several FG-
related loci had an effect on insulin release (basal or glucose-stimulated) and/or on
indices of proinsulin conversion, whereas only one locus (GCKR) was nominally
associated with insulin sensitivity.
6.4.1 Effects on insulin secretion
Basal insulin secretion
The balance between glucose uptake and glucose production in the liver maintains
FG levels. Hepatic glucose production is stimulated by glucagon, whereas insulin
prevents excessive release of glucose by the liver. Therefore, the association of 16 FG-
increasing loci with decreased HOMA-B (reflecting basal insulin secretion) reported
in a previous study [18] was not unexpected. Our results are in agreement with these
findings, although most of the associations were nominally significant, and only the
results of G6PC2, MTNR1B, and DGKB remained significant after correction for
multiple testing.
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SNPs of the three genes in G6PC2, MTNR1B, and DGKB displayed the largest effects
on HOMA-B (5-6% per  allele)  in  this  study. G6PC2 encodes glucose-6-phosphatase
catalytic subunit 2, which catalyses dephosphorylation of glucose-6-phosphate, thus
opposing the action of glucokinase, a glucose-sensor of the beta-cell modulating
insulin secretion. MTNR1B encodes the receptor 1B for melatonin, a hormone
playing an important role in the regulation of circadian rhythms with widespread
biological functions. Melatonin has an inhibitory effect on insulin secretion [296]. It is
likely that these variants enhance the expression of the gene or activity of the
protein, thereby increasing glucose levels. DGKB encodes for diacylglycerol kinase ,
which phosphorylates diacylglycerol (DAG). In the beta-cell, DAG activates protein
kinase C (PKC), which further leads to an increase in insulin secretion, whereas
phosphorylation of DAG terminates its action on PKC [297].
Glucose-stimulated insulin secretion
A defective first-phase insulin release to glucose stimulation is considered as a
characteristic feature of type 2 diabetes. The FG-increasing alleles at the MTNR1B
and TCF7L2 loci were significantly associated with impaired glucose-induced insulin
secretion. In addition, nominally significant associations with impaired glucose-
stimulated insulin secretion were found for CRY2, FADS1, GCK, and SLC30A8 (after
adjustment for age, BMI and Matsuda ISI). MTNR1B, TCF7L2 and SLC30A8, the
established type 2 diabetes risk loci, have been previously shown in several studies
to affect insulin secretion in OGTT or intravenous glucose-tolerance tests
[154,298,299]. Similar associations of FADS1 and GCK with an early-phase insulin
release during an OGTT (insulinogenic index) have also been reported [183].
GCK encodes glucokinase, which catalyzes the phosphorylation of
glucose in the beta-cell and liver. In the beta-cell, glucokinase catalyses the first step
of the glycolytic pathway and thereby functions as a glucose sensor regulating
insulin secretion [300]. Mutations in GCK have been implicated in several disorders
of glucose metabolism such as maturity-onset diabetes of the young (MODY) and
permanent neonatal diabetes [301]. The SNP of GCK examined in this study has also
been shown to increase the risk of type 2 diabetes [18]. FADS1 encodes fatty acid
desaturase 1, regulating the unsaturation of fatty acids. Non-esterified fatty acids
potentiate glucose-stimulated insulin secretion in murine beta-cells in vitro [302,303].
Interestingly, FADS1 had a larger effect on glucose-stimulated (InsAUC0-30/GluAUC0-
30)  than  on  basal  (HOMA-B)  insulin  secretion  in  the  current  study  (2.4  vs  0.8%  per
risk allele). CRY2 encodes  cryptochrome  2  (Cry2),  which  is  implicated  in  the
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regulation of the circadian feedback loop, and could therefore modulate the
circadian rhythm of insulin secretion. Interestingly, mice lacking Cry1 and Cry2
proteins exhibited impaired glucose tolerance due to decreased insulin secretion
[195-197].
Proinsulin processing
The effects on proinsulin processing, in addition to effects on insulin secretion, have
been  previously  reported  for TCF7L2, SLC30A8, and MTNR1B [154,167,268,304]. In
the  present  study,  FG-increasing  alleles  at  the TCF7L2 and SLC30A8 loci were
significantly associated with the high proinsulin/insulin ratio in the fasting state.
Impaired proinsulin processing is likely to be one of the mechanisms contributing to
impaired insulin secretion associated with these loci, although an increase in the
proinsulin/insulin ratio secondary to other abnormalities cannot be excluded.
Additionally, the MADD locus had the most prominent effects on proinsulin
conversion, with effect sizes 2-times larger than those of TCF7L2. MADD encodes
MAP-kinase activating death domain, which is involved in the regulation of cell
proliferation, survival and death, and is expressed especially in neoplastic cells [305].
Although the mechanism by which the MADD locus regulates proinsulin processing
is unclear, there could also be a role of the neighboring genes.
GCKR was nominally associated with decreased proinsulin/insulin ratio.
Since GCKR appears to regulate insulin sensitivity, decreased proinsulin/insulin
ratio  could  reflect  higher  demand  for  insulin  to  compensate  for  insulin  resistance.
An inverse relationship between insulin resistance and the low proinsulin/insulin
ratio in non-diabetic subjects has been reported previously [39].
6.4.2 Effects on insulin sensitivity
FG levels also depend on insulin sensitivity, particularly in the liver. A nominally
significant  reduction  in  Matsuda  ISI  was  detected  for  an  FG-increasing  allele  of
rs780094 of GCKR. This finding agrees with the results of previous studies
[15,306,307] and a meta-analysis of GWA studies, where GCKR was the sole FG-
related locus associated with HOMA-IR [18] and OGTT-derived indices of insulin
sensitivity [183]. GCKR encodes the glucokinase regulatory protein (GKRP) that
inhibits the effects of glucokinase on glycogen synthesis and gluconeogenesis in the
liver [122,308]. Moreover, impaired regulation of glucokinase by GKRP has been
implicated in the pathophysiology of the MODY2 [124,309], characterized by
impaired insulin secretion and increased hepatic glucose production [180,310].
59
Surprisingly,  no  significant  association  was  found  with  Liver  IR  index  probably
because of the very modest effects of these loci that might need even larger studies
with larger statistical power to be detected.
The effects of the tested SNPs on the FG level in our study were rather
similar to those reported in the meta-analysis [18], although only the effects of
G6PC2 and MTNR1B were  statistically  significant.  It  was  not  possible  to  confirm
associations for 5 SNPs (ADRA2A, FAM148A, GLIS3, MADD, and PROX1) probably
due to a limited statistical power of our study. We observed a larger effect of the
genetic risk score on the proinsulin/insulin ratio during an OGTT (increase by 42%)
than in the fasting state (increase by 27%) suggesting that the defect(s) in the
conversion of proinsulin to insulin becomes more apparent during glucose-
stimulation than in the fasting state, and could therefore be underestimated by
fasting measurements alone.
In summary, our study demonstrated that several newly confirmed
candidate loci for fasting hyperglycemia were associated especially with early-phase
insulin release and/or with indices of proinsulin-to-insulin conversion.
6.5 CONCLUDING REMARKS
Insulin resistance is one of the major pathophysiological features of type 2 diabetes.
It is known to be present in the prediabetic state several years before the
development of type 2 diabetes. Insulin resistance also regulates significantly the
levels of several CVD risk factors.
Insulin resistance can be observed in several tissues, especially in the
muscle,  liver  and  adipose  tissue.  Although  there  are  accurate  methods  to  measure
tissue-specific insulin resistance with the glucose clamp technique combined with
tracers, these methods are cumbersome and not feasible for application in large
population-based studies. Therefore, the availability of surrogate markers of tissue-
specific insulin resistance provides us with tools basing on which it is possible to
investigate the pathophysiology of insulin resistance at the population level.
During the last five years, GWA studies have identified a large number
of candidate genes and several risk loci that increase the risk of type 2 diabetes and
hyperglycemia. Many of these genes were novel and not predicted to play a
significant role in the pathophysiology of type 2 diabetes. Surprisingly, most of the
gene variants reported so far have been associated with impaired insulin secretion
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and  a  very  few  with  insulin  resistance.  Few  of  the  several  reasons  might  be  1)  the
lower heritability of insulin resistance, as lifestyle and the environment seems to
play a major role, 2) lack of good markers of insulin resistance that are able to
capture the modest effects of insulin resistance in different tissues and 3) lack
statistical power to detect these modest associations.
The current study led to the development of a novel Liver IR index that
correlated strongly with the gold standard measure for hepatic insulin resistance.
The index performed well irrespective of the obesity and glucose tolerance status in
the non-diabetic range. By applying this Liver IR index in the METSIM study, it was
possible to identify that type 2 diabetes risk loci in KCNJ11 and HHEX confer
increased hepatic insulin sensitivity. Furthermore, the Pro12 allele in PPARG was
found to confer predominantly adipocyte insulin resistance. These results
demonstrate that evaluation of tissue-specific insulin resistance is very likely to
increase the number of gene variants regulating insulin resistance. Our findings also
demonstrated the close connection between tissue-specific insulin resistance and
insulin secretion.
Insulin resistance significantly increases the risk of CVD. This
association was based on studies which applied whole-body level measures of
insulin resistance (euglycemic clamp or Matsuda ISI). No previous study has
examined the association of tissue-specific insulin resistance in a large population
based study. The current study demonstrated that insulin resistance, especially in
the liver, affects CVD risk factors, especially those involved in low-grade
inflammation and dyslipidemia. We further demonstrated that some of the SNPs
elevating fasting glucose also regulate proinsulin processing and insulin secretion.
However, we could not detect any significant association of these SNPs with Liver
IR index probably as their effect sizes are very modest. Their role as CVD risk factors
remain to be elucidated.
In spite of the development of new technologies of genetics during the
last  few  years,  common  variants  explain  only  a  small  proportion  of  the  genetic
variation of different clinical or laboratory traits. In the future, the application of
exome and whole genome sequencing might substantially increase our
understanding of the role of genetic factors regulating insulin secretion and insulin
resistance and how these modify the risk of type 2 diabetes.
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7. Summary
The main findings of the Studies I-IV were as follows:
Study I: A novel surrogate index for hepatic insulin resistance was developed that
correlates strongly with the gold-standard measure of hepatic insulin resistance in
non-diabetic subjects, irrespective of glucose tolerance and obesity status.
Study II: Among the type 2 diabetes risk loci, KCNJ11 rs5219 and HHEX rs1111875
were associated with increased liver insulin sensitivity whereas PPARG rs1801282
was associated with higher adipocyte insulin resistance. These results indicate that
type 2 diabetes risk loci might have tissue-specific effects.
Study III: Liver IR index reflecting hepatic insulin resistance correlated more
strongly with several cardiovascular risk factors than did Matsuda insulin sensitivity
index that reflects whole body insulin sensitivity. These results highlight the
important role of the liver in the risk of developing cardiovascular disease.
Study IV: Several confirmed candidate loci for fasting hyperglycemia were
associated especially  with  early-phase  insulin  release  or  with  indices  of  proinsulin-
to-insulin conversion emphasizing the important role of impaired insulin secretion
in fasting hyperglycemia.
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Insulin resistance is a major metabolic 
disturbance in type 2 diabetes and is ob-
served primarily in the muscle, liver and 
adipose tissue. This thesis introduces a 
novel surrogate index to estimate hepatic 
insulin resistance. It further examines the 
tissue specificity of reported type 2 diabe-
tes risk loci in the liver and adipose tissue 
insulin resistance. The study compares 
the association of liver and muscle insulin 
resistance indices with cardiovascular 
risk factors. Insulin resistance in the liver 
correlates more strongly with various 
cardiovascular risk factors revealing a 
critical role of the liver in cardiovascu-
lar health. Finally, the thesis examines 
mainly insulin release and proinsulin 
processing as possible mechanisms for 
the association of several genetic risk loci 
with hyperglycemia.
